Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).
Inflammation of any part of the KIDNEY.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
A mouse substrain that is genetically predisposed to the development of systemic lupus erythematosus-like syndrome, which has been found to be clinically similar to the human disease. It has been determined that this mouse strain carries a mutation in the fas gene. Also, the MRL/lpr is a useful model to study behavioral and cognitive deficits found in autoimmune diseases and the efficacy of immunosuppressive agents.
Inbred NZB mice are a strain of laboratory mice that spontaneously develop an autoimmune disease similar to human systemic lupus erythematosus (SLE), characterized by the production of autoantibodies, immune complex deposition, and glomerulonephritis.
Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.
A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue.
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.
A subcomponent of complement C1, composed of six copies of three polypeptide chains (A, B, and C), each encoded by a separate gene (C1QA; C1QB; C1QC). This complex is arranged in nine subunits (six disulfide-linked dimers of A and B, and three disulfide-linked homodimers of C). C1q has binding sites for antibodies (the heavy chain of IMMUNOGLOBULIN G or IMMUNOGLOBULIN M). The interaction of C1q and immunoglobulin activates the two proenzymes COMPLEMENT C1R and COMPLEMENT C1S, thus initiating the cascade of COMPLEMENT ACTIVATION via the CLASSICAL COMPLEMENT PATHWAY.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
A complex of antigenic proteins obtained from the brush border of kidney tubules. It contains two principal components LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-2 and LDL-RECEPTOR RELATED PROTEIN-ASSOCIATED PROTEIN. The name of this complex is derived from researcher, Dr. Walter Heymann, who developed an experimental model of membranous glomerulonephritis (GLOMERULONEPHRITIS) by injecting this antigenic complex into rats to induce an autoimmune response.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase.
Group of diseases mediated by the deposition of large soluble complexes of antigen and antibody with resultant damage to tissue. Besides SERUM SICKNESS and the ARTHUS REACTION, evidence supports a pathogenic role for immune complexes in many other IMMUNE SYSTEM DISEASES including GLOMERULONEPHRITIS, systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC) and POLYARTERITIS NODOSA.
A darkly stained mat-like EXTRACELLULAR MATRIX (ECM) that separates cell layers, such as EPITHELIUM from ENDOTHELIUM or a layer of CONNECTIVE TISSUE. The ECM layer that supports an overlying EPITHELIUM or ENDOTHELIUM is called basal lamina. Basement membrane (BM) can be formed by the fusion of either two adjacent basal laminae or a basal lamina with an adjacent reticular lamina of connective tissue. BM, composed mainly of TYPE IV COLLAGEN; glycoprotein LAMININ; and PROTEOGLYCAN, provides barriers as well as channels between interacting cell layers.
A chronic form of cutaneous lupus erythematosus (LUPUS ERYTHEMATOSUS, CUTANEOUS) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterized by the presence of discoid skin plaques showing varying degrees of edema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur.
A PREDNISOLONE derivative with similar anti-inflammatory action.
The layer of EXTRACELLULAR MATRIX that lies between the ENDOTHELIUM of the glomerular capillaries and the PODOCYTES of the inner or visceral layer of the BOWMAN CAPSULE. It is the product of these two cell types. It acts as a physical barrier and an ion-selective filter.
A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.
Long convoluted tubules in the nephrons. They collect filtrate from blood passing through the KIDNEY GLOMERULUS and process this filtrate into URINE. Each renal tubule consists of a BOWMAN CAPSULE; PROXIMAL KIDNEY TUBULE; LOOP OF HENLE; DISTAL KIDNEY TUBULE; and KIDNEY COLLECTING DUCT leading to the central cavity of the kidney (KIDNEY PELVIS) that connects to the URETER.
Creatinine is a waste product that's generated from muscle metabolism, typically filtered through the kidneys and released in urine, with increased levels in blood indicating impaired kidney function.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Mouse strains constructed to possess identical genotypes except for a difference at a single gene locus.
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B.
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
Administration of high doses of pharmaceuticals over short periods of time.
A group of inherited conditions characterized initially by HEMATURIA and slowly progressing to RENAL INSUFFICIENCY. The most common form is the Alport syndrome (hereditary nephritis with HEARING LOSS) which is caused by mutations in genes for TYPE IV COLLAGEN and defective GLOMERULAR BASEMENT MEMBRANE.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
Pathological processes of the KIDNEY or its component tissues.
Therapy with two or more separate preparations given for a combined effect.
Presence of blood in the urine.
Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.
Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
The thin membranous structure supporting the adjoining glomerular capillaries. It is composed of GLOMERULAR MESANGIAL CELLS and their EXTRACELLULAR MATRIX.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.
A plant genus of the family CELASTRACEAE that is a source of triterpenoids and diterpene epoxides such as triptolide.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN.
Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Abnormal immunoglobulins, especially IGG or IGM, that precipitate spontaneously when SERUM is cooled below 37 degrees Celsius. It is characteristic of CRYOGLOBULINEMIA.
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Smooth muscle-like cells adhering to the wall of the small blood vessels of the KIDNEY at the glomerulus and along the vascular pole of the glomerulus in the JUXTAGLOMERULAR APPARATUS. They are myofibroblasts with contractile and phagocytic properties. These cells and their MESANGIAL EXTRACELLULAR MATRIX constitute the GLOMERULAR MESANGIUM.
A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased hepatic albumin synthesis, increased albumin catabolism, altered albumin distribution, or albumin loss through the urine (ALBUMINURIA).
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
A form of fluorescent antibody technique utilizing a fluorochrome conjugated to an antibody, which is added directly to a tissue or cell suspension for the detection of a specific antigen. (Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
Methods and procedures for the diagnosis of diseases or dysfunction of the urinary tract or its organs or demonstration of its physiological processes.

T cell subsets in experimental lupus nephritis: modulation by bacterial superantigen. (1/1071)

Chronic graft-vs-host disease (GvH), induced by injection of DBA/2 lymphocytes into (C57BL/6 x DBA/2)F1 hybrids, is a murine model for lupus nephritis, associated with a Th2-dependent polyclonal B cell activation. The development of glomerulosclerosis in this model is preceded by a glomerular influx of LFA-1+ T cells. We investigated whether exposure to bacterial superantigen would modulate the course of this autoimmune syndrome. Injection of the bacterial superantigen staphylococcal enterotoxin B (SEB) in mice has been shown to induce the activation of TcRVbeta8+ T cells. Within 2 weeks after GvH induction, mice were injected twice with 20 microg of SEB and the following parameters were examined: cytokine and Ig profile, proteinuria and renal pathology. The second SEB injection induced in GvH mice an increased release of both interferon-gamma (IFN-gamma) and interleukin-10 (IL-10) as compared with control F1 mice. No differences were observed in IL-2 production. SEB-treated GvH mice demonstrated a delayed onset of proteinuria. Histological analysis of the kidney showed that SEB-challenged GvH mice displayed significantly more interstitial inflammation and mesangial proliferation together with more IgG2a deposits in glomeruli than non-injected GvH mice. From these results, we conclude that GvH mice are more responsive to SEB in terms of cytokine production and that bacterial infection can modulate the course of this renal disease from a membranous to a more proliferative type of nephropathy.  (+info)

Immunophilins, Refsum disease, and lupus nephritis: the peroxisomal enzyme phytanoyl-COA alpha-hydroxylase is a new FKBP-associated protein. (2/1071)

FKBP52 (FKBP59, FKBP4) is a "macro" immunophilin that, although sharing high structural and functional homologies in its amino-terminal domain with FKBP12 (FKBP1), does not have immunosuppressant activity when complexed with FK506, unlike FKBP12. To investigate the physiological function of FKBP52, we used the yeast two-hybrid system as an approach to find its potential protein partners and, from that, its cellular role. This methodology, which already has allowed us to find the FK506-binding protein (FKBP)-associated protein FAP48, also led to the detection of another FKBP-associated protein. Determination of the sequence of this protein permitted its identification as phytanoyl-CoA alpha-hydroxylase (PAHX), a peroxisomal enzyme that so far was unknown as an FKBP-associated protein. Inactivation of this enzyme is responsible for Refsum disease in humans. The protein also corresponds to the mouse protein LN1, which could be involved in the progress of lupus nephritis. We show here that PAHX has the physical capacity to interact with the FKBP12-like domain of FKBP52, but not with FKBP12, suggesting that it is a particular and specific target of FKBP52. Whereas the binding of calcineurin to FKBP12 is potentiated by FK506, the specific association of PAHX and FKBP52 is maintained in the presence of FK506. This observation suggests that PAHX is a serious candidate for studying the cellular signaling pathway(s) involving FKBP52 in the presence of immunosuppressant drugs.  (+info)

Analysis of MHC class II genes in the susceptibility to lupus in New Zealand mice. (3/1071)

Hybrids of New Zealand Black (NZB) and New Zealand White (NZW) mice spontaneously develop a disease similar to human systemic lupus erythematosus. MHC and non-MHC genes contribute to disease susceptibility in this murine model. Multiple studies have shown that the NZW H2z locus is strongly associated with the development of lupus-like disease in these mice. The susceptibility gene(s) within H2z is not known, but different lines of evidence have pointed to class II MHC genes, either H2-E or H2-A (Ez or Az in NZW). Recent studies from our laboratory showed that Ez does not supplant H2z in the contribution to lupus-like disease. In the present work we generated C57BL/10 (B10) mice transgenic for Aaz and Abz genes (designated B10.Az mice) and used a (B10.Az x NZB)F1 x NZB backcross to assess the contributions of Az genes to disease. A subset of backcross mice produced high levels of IgG autoantibodies and developed severe nephritis. However, no autoimmune phenotype was linked to the Az transgenes. Surprisingly, in the same backcross mice, inheritance of H2b from the nonautoimmune B10 strain was strongly linked with both autoantibody production and nephritis. Taken together with our previous Ez studies, the present work calls into question the importance of class II MHC genes for lupus susceptibility in this model and provides new insight into the role of MHC in lupus-like autoimmunity.  (+info)

Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. (4/1071)

Intraperitoneal injection of pristane induces a lupus-like disease in BALB/c and other non-autoimmune mice characterized by autoantibody production and the development of immune complex disease closely resembling lupus nephritis. Two subsets of autoantibodies are induced by pristane: IgG anti-DNA DNA and -chromatin autoantibodies are strongly IL-6-dependent, whereas IgG anti-nRNP/Sm and -Su antibodies are not. The present studies were carried out to examine the role of T cells in establishing this dichotomy between the production of anti-nRNP/Sm/Su versus anti-DNA/chromatin autoantibodies. Autoantibody production and renal disease were evaluated in athymic (nude) mice treated with pristane. BALB/c nu/nu mice spontaneously developed IgM and IgG anti-single-stranded (ss)DNA and -chromatin, but not anti-nRNP/Sm or -Su, autoantibodies. Pristane treatment increased the levels of IgG anti-chromatin antibodies in nu/nu mice, but did not induce production of anti-nRNP/Sm or -Su antibodies. In contrast, BALB/c nu/+ and +/+ control mice did not spontaneously produce autoantibodies, whereas anti-nRNP/Sm and -Su autoantibodies were induced by pristane in approx. 50% of nu/+ and +/+ mice and anti-DNA/chromatin antibodies at lower frequencies. Nude mice spontaneously developed mild renal lesions that were marginally affected by pristane, but were generally milder than the lesions developing in pristane-treated nu/+ and +/+ mice. The data provide further evidence that two distinct pathways with different cytokine and T cell requirements are involved in autoantibody formation in pristane-induced lupus. This dichotomy may be relevant to understanding differences in the regulation of anti-DNA versus anti-nRNP/Sm autoantibodies in systemic lupus erythematosus, as well as the association of anti-DNA, but not anti-nRNP/Sm, with lupus nephritis.  (+info)

Mycophenolate mofetil therapy in lupus nephritis: clinical observations. (5/1071)

Controlled clinical trials in renal transplantation have demonstrated that mycophenolate mofetil is well tolerated and has lower renal transplant rejection rates than azathioprine regimens. This study reports on the clinical experiences at two institutions with mycophenolate mofetil (MMF) for severe lupus nephritis. Twelve patients with relapsing or resistant nephritis previously treated with cyclophosphamide therapy and one patient who refused cyclophosphamide as initial therapy for diffuse proliferative nephritis but accepted MMF were included. During combined MMF/prednisone therapy, serum creatinine values remained normal or declined from elevated values: mean change in serum creatinine was -0.26+/-0.46 microM/L, P = 0.039. Proteinuria significantly decreased: mean change in urine protein-to-creatinine ratios was -2.53+/-3.76, P = 0.039. Decreased serum complement component C3 and elevated anti-double-stranded DNA antibody levels at baseline improved in some, but not all, patients. The mean initial dose of MMF was 0.92 g/d (range, 0.5 to 2 g/d). The mean duration of therapy was 12.9 mo (range, 3 to 24 mo). Adverse events included herpes simplex stomatitis associated with severe leukopenia (n = 1), asymptomatic leukopenia (n = 2), nausea/ diarrhea (n = 2), thinning of scalp hair (n = 1), pancreatitis (n = 1), and pneumonia without leukopenia (n = 1). Recurrence of the pancreatitis led to discontinuation of MMF in this patient; all other adverse events resolved with dose reduction. It is concluded that MMF is well tolerated and has possible efficacy in controlling major renal manifestations of systemic lupus erythematosus. Controlled clinical trials are needed to define the role of MMF in the management of lupus nephritis.  (+info)

Mice with early onset of death (EOD) due to lupus glomerulonephritis. (6/1071)

Both MRL-lpr/lpr (lpr) and BXSB mice fall victim to autoimmune disease as a function of age. To combine their properties, brother-sister mating of (female lpr x male BXSB)F1 mice was done. Mice for mating were selected according to indicators of early onset of glomerulonephritis and subsequent early death (i.e., EOD). This mating was continued for more than 16 generations. The EOD mice thus established had homozygous H-2k/k, lpr/lpr, and possible yaa/- (in the case of males). The average life span of males was 83 days while that of females was 126 days. After 12 weeks of age, the majority (> 80%) of male EOD mice were characterized by the abnormality of urine due to glomerulonephritis. We then characterized how glomerulonephritis was evoked, especially in terms of expanding lymphocyte subsets in various immune organs. Similar to the case of parental lpr mice, the major expanding cells were CD4-8-B220+ TCRint cells in the immune organs and kidney. In addition, myeloid cells were found to infiltrate the kidney. This massive infiltration of both TCRint cells and myeloid cells might be responsible for the onset of acute glomerulonephritis. Even after more than 50 generations, these EOD mice still carry both lpr and yaa genes. These results suggest that EOD mice might be a very useful tool for the study of acute lupus glomerulonephritis which is evoked by the genetic abnormalities.  (+info)

Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. (7/1071)

In the (SWR x NZB)F1 mouse model of lupus, we previously localized the critical autoepitopes for nephritogenic autoantibody-inducing Th cells in the core histones of nucleosomes at aa positions 10-33 of H2B and 16-39 and 71-94 of H4. A brief therapy with the peptides administered i.v. to 3-mo-old prenephritic (SWR x NZB)F1 mice that were already producing pathogenic autoantibodies markedly delayed the onset of severe lupus nephritis. Strikingly, chronic therapy with the peptides injected into 18-mo-old (SWR x NZB)F1 mice with established glomerulonephritis prolonged survival and even halted the progression of renal disease. Remarkably, tolerization with any one of the nucleosomal peptides impaired autoimmune T cell help, inhibiting the production of multiple pathogenic autoantibodies. However, cytokine production or proliferative responses to the peptides were not grossly changed by the therapy. Moreover, suppressor T cells were not detected in the treated mice. Most interestingly, the best therapeutic effect was obtained with nucleosomal peptide H416-39, which had a tolerogenic effect not only on autoimmune Th cells, but autoimmune B cells as well, because this peptide contained both T and B cell autoepitopes. These studies show that the pathogenic T and B cells of lupus, despite intrinsic defects in activation thresholds, are still susceptible to autoantigen-specific tolerogens.  (+info)

Altered expression level of a systemic nuclear autoantigen determines the fate of immune response to self. (8/1071)

One of the hallmarks of systemic autoimmune diseases is immune responses to systemic nuclear autoantigens. We have examined the fate of the immune response against a nuclear autoantigen using human U1 small nuclear ribonucleoprotein-A protein (HuA) transgenic (Tg) mice by adoptive transfer of autoreactive lymphocytes. We obtained two Tg lines that have different expression levels of the transgene. After spleen cells from HuA-immunized wild-type mice were transferred to Tg mice and their non-Tg littermates, these recipients were injected with HuA/IFA to induce a recall memory response. HAB69, which expressed a lower amount of HuA, exhibited a vigorous increase in the autoantibody level and glomerulonephritis. Moreover, the autoreactivity spread to 70K autoantigen. Alternatively, in HAB64, which expressed a higher amount of HuA, the production of autoantibody was markedly suppressed. The immune response to HuA autoantigen was impaired as demonstrated in a both delayed-type hypersensitivity response and proliferation assay. This inhibition was Ag-specific and was mediated by T cells. These data suggest that the expression level of systemic autoantigens influences the outcome of the immune response to self.  (+info)

Lupus nephritis is a type of kidney inflammation (nephritis) that can occur in people with systemic lupus erythematosus (SLE), an autoimmune disease. In lupus nephritis, the immune system produces abnormal antibodies that attack the tissues of the kidneys, leading to inflammation and damage. The condition can cause a range of symptoms, including proteinuria (protein in the urine), hematuria (blood in the urine), hypertension (high blood pressure), and eventually kidney failure if left untreated. Lupus nephritis is typically diagnosed through a combination of medical history, physical examination, laboratory tests, and imaging studies. Treatment may include medications to suppress the immune system and control inflammation, such as corticosteroids and immunosuppressive drugs.

Nephritis is a medical term that refers to inflammation of the kidneys, specifically affecting the glomeruli - the tiny filtering units inside the kidneys. The condition can cause damage to the glomeruli, leading to impaired kidney function and the leakage of protein and blood into the urine.

Nephritis can result from a variety of causes, including infections, autoimmune disorders, and exposure to certain medications or toxins. Depending on the severity and underlying cause, nephritis may be treated with medications, dietary modifications, or other therapies aimed at reducing inflammation and preserving kidney function. In severe cases, hospitalization and more intensive treatments may be necessary.

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that can affect almost any organ or system in the body. In SLE, the immune system produces an exaggerated response, leading to the production of autoantibodies that attack the body's own cells and tissues, causing inflammation and damage. The symptoms and severity of SLE can vary widely from person to person, but common features include fatigue, joint pain, skin rashes (particularly a "butterfly" rash across the nose and cheeks), fever, hair loss, and sensitivity to sunlight.

Systemic lupus erythematosus can also affect the kidneys, heart, lungs, brain, blood vessels, and other organs, leading to a wide range of symptoms such as kidney dysfunction, chest pain, shortness of breath, seizures, and anemia. The exact cause of SLE is not fully understood, but it is believed to involve a combination of genetic, environmental, and hormonal factors. Treatment typically involves medications to suppress the immune system and manage symptoms, and may require long-term management by a team of healthcare professionals.

Antinuclear antibodies (ANA) are a type of autoantibody that target structures found in the nucleus of a cell. These antibodies are produced by the immune system and attack the body's own cells and tissues, leading to inflammation and damage. The presence of ANA is often used as a marker for certain autoimmune diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome, rheumatoid arthritis, scleroderma, and polymyositis.

ANA can be detected through a blood test called the antinuclear antibody test. A positive result indicates the presence of ANA in the blood, but it does not necessarily mean that a person has an autoimmune disease. Further testing is usually needed to confirm a diagnosis and determine the specific type of autoantibodies present.

It's important to note that ANA can also be found in healthy individuals, particularly as they age. Therefore, the test results should be interpreted in conjunction with other clinical findings and symptoms.

'Mice, Inbred MRL-lpr' refers to a specific strain of laboratory mice that are used in biomedical research. The 'MRL' part of the name stands for the breeding colony where they were originally developed, which is the Mouse Repository at the Jackson Laboratory in Bar Harbor, Maine. The 'lpr' designation indicates that these mice carry a mutation in the Fas gene, also known as lpr (lymphoproliferation) gene, which leads to an autoimmune disorder characterized by lymphadenopathy (enlarged lymph nodes), splenomegaly (enlarged spleen), and production of autoantibodies.

The MRL-lpr mice are known for their accelerated aging phenotype, which includes the development of a variety of age-related diseases such as atherosclerosis, osteoporosis, and cancer. They also develop a severe form of systemic lupus erythematosus (SLE), an autoimmune disease that affects many organs in the body. The MRL-lpr mice are widely used as a model to study the pathogenesis of SLE and other autoimmune diseases, as well as to test potential therapies for these conditions.

It is important to note that while inbred mouse strains like MRL-lpr provide valuable insights into human disease mechanisms, they do not perfectly replicate all aspects of human disease, and results obtained in mice may not always translate directly to humans. Therefore, findings from mouse studies should be interpreted with caution and validated in human studies before being applied in clinical practice.

'NZB mice' is a term used to refer to an inbred strain of laboratory mice that are genetically identical to each other and have been used extensively in biomedical research. The 'NZB' designation stands for "New Zealand Black," which refers to the coat color of these mice.

NZB mice are known to spontaneously develop an autoimmune disease that is similar to human systemic lupus erythematosus (SLE), a chronic inflammatory disorder caused by an overactive immune system. This makes them a valuable model for studying the genetic and environmental factors that contribute to the development of SLE, as well as for testing new therapies and treatments.

It's important to note that while NZB mice are an inbred strain, they may still exhibit some variability in their disease phenotype due to genetic modifiers or environmental influences. Therefore, researchers often use large cohorts of mice and standardized experimental conditions to ensure the reproducibility and reliability of their findings.

Glomerulonephritis is a medical condition that involves inflammation of the glomeruli, which are the tiny blood vessel clusters in the kidneys that filter waste and excess fluids from the blood. This inflammation can impair the kidney's ability to filter blood properly, leading to symptoms such as proteinuria (protein in the urine), hematuria (blood in the urine), edema (swelling), hypertension (high blood pressure), and eventually kidney failure.

Glomerulonephritis can be acute or chronic, and it may occur as a primary kidney disease or secondary to other medical conditions such as infections, autoimmune disorders, or vasculitis. The diagnosis of glomerulonephritis typically involves a combination of medical history, physical examination, urinalysis, blood tests, and imaging studies, with confirmation often requiring a kidney biopsy. Treatment depends on the underlying cause and severity of the disease but may include medications to suppress inflammation, control blood pressure, and manage symptoms.

A kidney glomerulus is a functional unit in the nephron of the kidney. It is a tuft of capillaries enclosed within a structure called Bowman's capsule, which filters waste and excess fluids from the blood. The glomerulus receives blood from an afferent arteriole and drains into an efferent arteriole.

The process of filtration in the glomerulus is called ultrafiltration, where the pressure within the glomerular capillaries drives plasma fluid and small molecules (such as ions, glucose, amino acids, and waste products) through the filtration membrane into the Bowman's space. Larger molecules, like proteins and blood cells, are retained in the blood due to their larger size. The filtrate then continues down the nephron for further processing, eventually forming urine.

Proteinuria is a medical term that refers to the presence of excess proteins, particularly albumin, in the urine. Under normal circumstances, only small amounts of proteins should be found in the urine because the majority of proteins are too large to pass through the glomeruli, which are the filtering units of the kidneys.

However, when the glomeruli become damaged or diseased, they may allow larger molecules such as proteins to leak into the urine. Persistent proteinuria is often a sign of kidney disease and can indicate damage to the glomeruli. It is usually detected through a routine urinalysis and may be confirmed with further testing.

The severity of proteinuria can vary, and it can be a symptom of various underlying conditions such as diabetes, hypertension, glomerulonephritis, and other kidney diseases. Treatment for proteinuria depends on the underlying cause and may include medications to control blood pressure, manage diabetes, or reduce protein loss in the urine.

A kidney, in medical terms, is one of two bean-shaped organs located in the lower back region of the body. They are essential for maintaining homeostasis within the body by performing several crucial functions such as:

1. Regulation of water and electrolyte balance: Kidneys help regulate the amount of water and various electrolytes like sodium, potassium, and calcium in the bloodstream to maintain a stable internal environment.

2. Excretion of waste products: They filter waste products from the blood, including urea (a byproduct of protein metabolism), creatinine (a breakdown product of muscle tissue), and other harmful substances that result from normal cellular functions or external sources like medications and toxins.

3. Endocrine function: Kidneys produce several hormones with important roles in the body, such as erythropoietin (stimulates red blood cell production), renin (regulates blood pressure), and calcitriol (activated form of vitamin D that helps regulate calcium homeostasis).

4. pH balance regulation: Kidneys maintain the proper acid-base balance in the body by excreting either hydrogen ions or bicarbonate ions, depending on whether the blood is too acidic or too alkaline.

5. Blood pressure control: The kidneys play a significant role in regulating blood pressure through the renin-angiotensin-aldosterone system (RAAS), which constricts blood vessels and promotes sodium and water retention to increase blood volume and, consequently, blood pressure.

Anatomically, each kidney is approximately 10-12 cm long, 5-7 cm wide, and 3 cm thick, with a weight of about 120-170 grams. They are surrounded by a protective layer of fat and connected to the urinary system through the renal pelvis, ureters, bladder, and urethra.

Autoantibodies are defined as antibodies that are produced by the immune system and target the body's own cells, tissues, or organs. These antibodies mistakenly identify certain proteins or molecules in the body as foreign invaders and attack them, leading to an autoimmune response. Autoantibodies can be found in various autoimmune diseases such as rheumatoid arthritis, lupus, and thyroiditis. The presence of autoantibodies can also be used as a diagnostic marker for certain conditions.

Immunosuppressive agents are medications that decrease the activity of the immune system. They are often used to prevent the rejection of transplanted organs and to treat autoimmune diseases, where the immune system mistakenly attacks the body's own tissues. These drugs work by interfering with the immune system's normal responses, which helps to reduce inflammation and damage to tissues. However, because they suppress the immune system, people who take immunosuppressive agents are at increased risk for infections and other complications. Examples of immunosuppressive agents include corticosteroids, azathioprine, cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus.

Mycophenolic Acid (MPA) is an immunosuppressive drug that is primarily used to prevent rejection in organ transplantation. It works by inhibiting the enzyme inosine monophosphate dehydrogenase, which is a key enzyme for the de novo synthesis of guanosine nucleotides, an essential component for the proliferation of T and B lymphocytes. By doing this, MPA reduces the activity of the immune system, thereby preventing it from attacking the transplanted organ.

Mycophenolic Acid is available in two forms: as the sodium salt (Mycophenolate Sodium) and as the morpholinoethyl ester (Mycophenolate Mofetil), which is rapidly hydrolyzed to Mycophenolic Acid after oral administration. Common side effects of MPA include gastrointestinal symptoms such as diarrhea, nausea, and vomiting, as well as an increased risk of infections due to its immunosuppressive effects.

Membranoproliferative Glomerulonephritis (MPGN) is a type of glomerulonephritis, which is a group of kidney disorders characterized by inflammation and damage to the glomeruli, the tiny blood vessels in the kidneys responsible for filtering waste and excess fluids from the blood.

MPGN is specifically characterized by thickening of the glomerular basement membrane and proliferation (increased number) of cells in the mesangium, a region within the glomerulus. This condition can be primary or secondary to other diseases such as infections, autoimmune disorders, or monoclonal gammopathies.

MPGN is typically classified into three types based on the pattern of injury seen on electron microscopy: Type I, Type II (Dense Deposit Disease), and Type III. Each type has distinct clinical features, laboratory findings, and treatment approaches. Symptoms of MPGN may include hematuria (blood in urine), proteinuria (protein in urine), hypertension (high blood pressure), edema (swelling), and eventually progress to chronic kidney disease or end-stage renal disease if left untreated.

A biopsy is a medical procedure in which a small sample of tissue is taken from the body to be examined under a microscope for the presence of disease. This can help doctors diagnose and monitor various medical conditions, such as cancer, infections, or autoimmune disorders. The type of biopsy performed will depend on the location and nature of the suspected condition. Some common types of biopsies include:

1. Incisional biopsy: In this procedure, a surgeon removes a piece of tissue from an abnormal area using a scalpel or other surgical instrument. This type of biopsy is often used when the lesion is too large to be removed entirely during the initial biopsy.

2. Excisional biopsy: An excisional biopsy involves removing the entire abnormal area, along with a margin of healthy tissue surrounding it. This technique is typically employed for smaller lesions or when cancer is suspected.

3. Needle biopsy: A needle biopsy uses a thin, hollow needle to extract cells or fluid from the body. There are two main types of needle biopsies: fine-needle aspiration (FNA) and core needle biopsy. FNA extracts loose cells, while a core needle biopsy removes a small piece of tissue.

4. Punch biopsy: In a punch biopsy, a round, sharp tool is used to remove a small cylindrical sample of skin tissue. This type of biopsy is often used for evaluating rashes or other skin abnormalities.

5. Shave biopsy: During a shave biopsy, a thin slice of tissue is removed from the surface of the skin using a sharp razor-like instrument. This technique is typically used for superficial lesions or growths on the skin.

After the biopsy sample has been collected, it is sent to a laboratory where a pathologist will examine the tissue under a microscope and provide a diagnosis based on their findings. The results of the biopsy can help guide further treatment decisions and determine the best course of action for managing the patient's condition.

Membranous glomerulonephritis (MGN) is a kidney disorder that leads to the inflammation and damage of the glomeruli, which are the tiny blood vessels in the kidneys responsible for filtering waste and excess fluids from the blood. In MGN, the membrane that surrounds the glomerular capillaries becomes thickened and damaged due to the deposit of immune complexes, primarily composed of antibodies and antigens.

The onset of membranous glomerulonephritis can be either primary (idiopathic) or secondary to various underlying conditions such as autoimmune diseases (like systemic lupus erythematosus), infections (hepatitis B or C, syphilis, endocarditis), medications, or malignancies.

The symptoms of membranous glomerulonephritis may include:

1. Proteinuria - the presence of excess protein, specifically albumin, in the urine. This can lead to nephrotic syndrome, characterized by heavy protein loss in urine, edema (swelling), hypoalbuminemia (low blood albumin levels), and hyperlipidemia (high blood lipid levels).
2. Hematuria - the presence of red blood cells in the urine, which can be visible or microscopic.
3. Hypertension - high blood pressure.
4. Edema - swelling in various body parts due to fluid retention.
5. Nephrotic range proteinuria (protein loss greater than 3.5 grams per day) and/or nephritic syndrome (a combination of hematuria, proteinuria, hypertension, and kidney dysfunction) can be observed in some cases.

The diagnosis of membranous glomerulonephritis typically involves a thorough medical history, physical examination, urinalysis, blood tests, and imaging studies. A definitive diagnosis often requires a kidney biopsy to assess the glomerular structure and the nature of the immune complex deposits. Treatment depends on the underlying cause and severity of the disease and may include corticosteroids, immunosuppressants, blood pressure management, and supportive care for symptoms like edema and proteinuria.

Complement C1q is a protein that is part of the complement system, which is a group of proteins in the blood that help to eliminate pathogens and damaged cells from the body. C1q is the first component of the classical complement pathway, which is activated by the binding of C1q to antibodies that are attached to the surface of a pathogen or damaged cell.

C1q is composed of six identical polypeptide chains, each containing a collagen-like region and a globular head region. The globular heads can bind to various structures, including the Fc regions of certain antibodies, immune complexes, and some types of cells. When C1q binds to an activating surface, it triggers a series of proteolytic reactions that lead to the activation of other complement components and the formation of the membrane attack complex (MAC), which can punch holes in the membranes of pathogens or damaged cells, leading to their destruction.

In addition to its role in the immune system, C1q has also been found to have roles in various physiological processes, including tissue remodeling, angiogenesis, and the clearance of apoptotic cells. Dysregulation of the complement system, including abnormalities in C1q function, has been implicated in a variety of diseases, including autoimmune disorders, inflammatory diseases, and neurodegenerative conditions.

An antigen-antibody complex is a type of immune complex that forms when an antibody binds to a specific antigen. An antigen is any substance that triggers an immune response, while an antibody is a protein produced by the immune system to neutralize or destroy foreign substances like antigens.

When an antibody binds to an antigen, it forms a complex that can be either soluble or insoluble. Soluble complexes are formed when the antigen is small and can move freely through the bloodstream. Insoluble complexes, on the other hand, are formed when the antigen is too large to move freely, such as when it is part of a bacterium or virus.

The formation of antigen-antibody complexes plays an important role in the immune response. Once formed, these complexes can be recognized and cleared by other components of the immune system, such as phagocytes, which help to prevent further damage to the body. However, in some cases, the formation of large numbers of antigen-antibody complexes can lead to inflammation and tissue damage, contributing to the development of certain autoimmune diseases.

Azathioprine is an immunosuppressive medication that is used to prevent the rejection of transplanted organs and to treat autoimmune diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease. It works by suppressing the activity of the immune system, which helps to reduce inflammation and prevent the body from attacking its own tissues.

Azathioprine is a prodrug that is converted into its active form, 6-mercaptopurine, in the body. This medication can have significant side effects, including decreased white blood cell count, increased risk of infection, and liver damage. It may also increase the risk of certain types of cancer, particularly skin cancer and lymphoma.

Healthcare professionals must carefully monitor patients taking azathioprine for these potential side effects. They may need to adjust the dosage or stop the medication altogether if serious side effects occur. Patients should also take steps to reduce their risk of infection and skin cancer, such as practicing good hygiene, avoiding sun exposure, and using sunscreen.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

Heymann nephritis antigenic complex, also known as PLA2R (Phospholipase A2 Receptor), is a protein found on the surface of glomerular podocytes in the kidney. It is the target antigen in Heymann nephritis, an experimental model of membranous nephropathy, a kidney disorder characterized by the accumulation of immune complexes on the glomerular basement membrane leading to proteinuria and potential kidney failure. In this model, immunization with the Heymann nephritis antigenic complex induces the formation of antibodies against PLA2R, resulting in the development of membranous nephropathy.

In recent years, it has been discovered that PLA2R is also the target antigen in a significant proportion of patients with primary membranous nephropathy, making it an important biomarker for this disease and a potential therapeutic target.

Prednisolone is a synthetic glucocorticoid drug, which is a class of steroid hormones. It is commonly used in the treatment of various inflammatory and autoimmune conditions due to its potent anti-inflammatory and immunosuppressive effects. Prednisolone works by binding to specific receptors in cells, leading to changes in gene expression that reduce the production of substances involved in inflammation, such as cytokines and prostaglandins.

Prednisolone is available in various forms, including tablets, syrups, and injectable solutions. It can be used to treat a wide range of medical conditions, including asthma, rheumatoid arthritis, inflammatory bowel disease, allergies, skin conditions, and certain types of cancer.

Like other steroid medications, prednisolone can have significant side effects if used in high doses or for long periods of time. These may include weight gain, mood changes, increased risk of infections, osteoporosis, diabetes, and adrenal suppression. As a result, the use of prednisolone should be closely monitored by a healthcare professional to ensure that its benefits outweigh its risks.

Cyclophosphamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. This helps to stop the spread of cancer in the body. Cyclophosphamide is used to treat various types of cancer, including lymphoma, leukemia, multiple myeloma, and breast cancer. It can be given orally as a tablet or intravenously as an injection.

Cyclophosphamide can also have immunosuppressive effects, which means it can suppress the activity of the immune system. This makes it useful in treating certain autoimmune diseases, such as rheumatoid arthritis and lupus. However, this immunosuppression can also increase the risk of infections and other side effects.

Like all chemotherapy medications, cyclophosphamide can cause a range of side effects, including nausea, vomiting, hair loss, fatigue, and increased susceptibility to infections. It is important for patients receiving cyclophosphamide to be closely monitored by their healthcare team to manage these side effects and ensure the medication is working effectively.

Complement C3 is a protein that plays a central role in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Complement C3 can be activated through three different pathways: the classical pathway, the lectin pathway, and the alternative pathway. Once activated, it breaks down into two fragments, C3a and C3b.

C3a is an anaphylatoxin that helps to recruit immune cells to the site of infection or injury, while C3b plays a role in opsonization, which is the process of coating pathogens or damaged cells with proteins to make them more recognizable to the immune system. Additionally, C3b can also activate the membrane attack complex (MAC), which forms a pore in the membrane of target cells leading to their lysis or destruction.

In summary, Complement C3 is an important protein in the complement system that helps to identify and eliminate pathogens and damaged cells from the body through various mechanisms.

Immune complex diseases are medical conditions that occur when the immune system produces an abnormal response to certain antigens, leading to the formation and deposition of immune complexes in various tissues and organs. These immune complexes consist of antibodies bound to antigens, which can trigger an inflammatory reaction and damage the surrounding tissue.

Immune complex diseases can be classified into two categories: acute and chronic. Acute immune complex diseases include serum sickness and hypersensitivity vasculitis, while chronic immune complex diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis, and membranoproliferative glomerulonephritis.

The symptoms of immune complex diseases depend on the location and extent of tissue damage. They can range from mild to severe and may include fever, joint pain, skin rashes, kidney dysfunction, and neurological problems. Treatment typically involves medications that suppress the immune system and reduce inflammation, such as corticosteroids, immunosuppressants, and anti-inflammatory drugs.

The basement membrane is a thin, specialized layer of extracellular matrix that provides structural support and separates epithelial cells (which line the outer surfaces of organs and blood vessels) from connective tissue. It is composed of two main layers: the basal lamina, which is produced by the epithelial cells, and the reticular lamina, which is produced by the connective tissue. The basement membrane plays important roles in cell adhesion, migration, differentiation, and survival.

The basal lamina is composed mainly of type IV collagen, laminins, nidogens, and proteoglycans, while the reticular lamina contains type III collagen, fibronectin, and other matrix proteins. The basement membrane also contains a variety of growth factors and cytokines that can influence cell behavior.

Defects in the composition or organization of the basement membrane can lead to various diseases, including kidney disease, eye disease, and skin blistering disorders.

Discoid Lupus Erythematosus (DLE) is a chronic autoimmune disease that primarily affects the skin. It is a subtype of Cutaneous Lupus Erythematosus (CLE). DLE is characterized by coin-shaped, disc-like rashes on the face, scalp, and other sun-exposed areas of the body. These lesions are often red, scaly, and may cause scarring and pigmentation changes. Unlike Systemic Lupus Erythematosus (SLE), DLE typically does not affect internal organs, but in some cases, it can progress to SLE. The exact cause of DLE is unknown, but it is believed to be related to a combination of genetic, environmental, and hormonal factors that trigger an abnormal immune response. Treatment for DLE may include topical creams, oral medications, and avoidance of sun exposure.

Methylprednisolone is a synthetic glucocorticoid drug, which is a class of hormones that naturally occur in the body and are produced by the adrenal gland. It is often used to treat various medical conditions such as inflammation, allergies, and autoimmune disorders. Methylprednisolone works by reducing the activity of the immune system, which helps to reduce symptoms such as swelling, pain, and redness.

Methylprednisolone is available in several forms, including tablets, oral suspension, and injectable solutions. It may be used for short-term or long-term treatment, depending on the condition being treated. Common side effects of methylprednisolone include increased appetite, weight gain, insomnia, mood changes, and increased susceptibility to infections. Long-term use of methylprednisolone can lead to more serious side effects such as osteoporosis, cataracts, and adrenal suppression.

It is important to note that methylprednisolone should be used under the close supervision of a healthcare provider, as it can cause serious side effects if not used properly. The dosage and duration of treatment will depend on various factors such as the patient's age, weight, medical history, and the condition being treated.

The Glomerular Basement Membrane (GBM) is a part of the filtration barrier in the nephron of the kidney. It is a thin, porous sheet of extracellular matrix that lies between the glomerular endothelial cells and the visceral epithelial cells (podocytes). The GBM plays a crucial role in the process of ultrafiltration, allowing the passage of water and small molecules while preventing the loss of larger proteins into the urine. It is composed mainly of type IV collagen, laminin, nidogen, and heparan sulfate proteoglycans. Certain kidney diseases, such as Goodpasture's disease and some forms of glomerulonephritis, can involve damage to the GBM.

Henoch-Schönlein purpura (HSP) is a type of small vessel vasculitis, which is a condition characterized by inflammation of the blood vessels. HSP primarily affects children, but it can occur in adults as well. It is named after two German physicians, Eduard Heinrich Henoch and Johann Schönlein, who first described the condition in the mid-19th century.

The main feature of HSP is a purpuric rash, which is a type of rash that appears as small, red or purple spots on the skin. The rash is caused by leakage of blood from the small blood vessels (capillaries) beneath the skin. In HSP, this rash typically occurs on the legs and buttocks, but it can also affect other parts of the body, such as the arms, face, and trunk.

In addition to the purpuric rash, HSP is often accompanied by other symptoms, such as joint pain and swelling, abdominal pain, nausea, vomiting, and diarrhea. In severe cases, it can also affect the kidneys, leading to hematuria (blood in the urine) and proteinuria (protein in the urine).

The exact cause of HSP is not known, but it is thought to be related to an abnormal immune response to certain triggers, such as infections or medications. Treatment typically involves supportive care, such as pain relief and fluid replacement, as well as medications to reduce inflammation and suppress the immune system. In most cases, HSP resolves on its own within a few weeks or months, but it can lead to serious complications in some individuals.

Kidney tubules are the structural and functional units of the kidney responsible for reabsorption, secretion, and excretion of various substances. They are part of the nephron, which is the basic unit of the kidney's filtration and reabsorption process.

There are three main types of kidney tubules:

1. Proximal tubule: This is the initial segment of the kidney tubule that receives the filtrate from the glomerulus. It is responsible for reabsorbing approximately 65% of the filtrate, including water, glucose, amino acids, and electrolytes.
2. Loop of Henle: This U-shaped segment of the tubule consists of a thin descending limb, a thin ascending limb, and a thick ascending limb. The loop of Henle helps to concentrate urine by creating an osmotic gradient that allows water to be reabsorbed in the collecting ducts.
3. Distal tubule: This is the final segment of the kidney tubule before it empties into the collecting duct. It is responsible for fine-tuning the concentration of electrolytes and pH balance in the urine by selectively reabsorbing or secreting substances such as sodium, potassium, chloride, and hydrogen ions.

Overall, kidney tubules play a critical role in maintaining fluid and electrolyte balance, regulating acid-base balance, and removing waste products from the body.

Creatinine is a waste product that's produced by your muscles and removed from your body by your kidneys. Creatinine is a breakdown product of creatine, a compound found in meat and fish, as well as in the muscles of vertebrates, including humans.

In healthy individuals, the kidneys filter out most of the creatinine and eliminate it through urine. However, when the kidneys are not functioning properly, creatinine levels in the blood can rise. Therefore, measuring the amount of creatinine in the blood or urine is a common way to test how well the kidneys are working. High creatinine levels in the blood may indicate kidney damage or kidney disease.

Autoantigens are substances that are typically found in an individual's own body, but can stimulate an immune response because they are recognized as foreign by the body's own immune system. In autoimmune diseases, the immune system mistakenly attacks and damages healthy tissues and organs because it recognizes some of their components as autoantigens. These autoantigens can be proteins, DNA, or other molecules that are normally present in the body but have become altered or exposed due to various factors such as infection, genetics, or environmental triggers. The immune system then produces antibodies and activates immune cells to attack these autoantigens, leading to tissue damage and inflammation.

A biological marker, often referred to as a biomarker, is a measurable indicator that reflects the presence or severity of a disease state, or a response to a therapeutic intervention. Biomarkers can be found in various materials such as blood, tissues, or bodily fluids, and they can take many forms, including molecular, histologic, radiographic, or physiological measurements.

In the context of medical research and clinical practice, biomarkers are used for a variety of purposes, such as:

1. Diagnosis: Biomarkers can help diagnose a disease by indicating the presence or absence of a particular condition. For example, prostate-specific antigen (PSA) is a biomarker used to detect prostate cancer.
2. Monitoring: Biomarkers can be used to monitor the progression or regression of a disease over time. For instance, hemoglobin A1c (HbA1c) levels are monitored in diabetes patients to assess long-term blood glucose control.
3. Predicting: Biomarkers can help predict the likelihood of developing a particular disease or the risk of a negative outcome. For example, the presence of certain genetic mutations can indicate an increased risk for breast cancer.
4. Response to treatment: Biomarkers can be used to evaluate the effectiveness of a specific treatment by measuring changes in the biomarker levels before and after the intervention. This is particularly useful in personalized medicine, where treatments are tailored to individual patients based on their unique biomarker profiles.

It's important to note that for a biomarker to be considered clinically valid and useful, it must undergo rigorous validation through well-designed studies, including demonstrating sensitivity, specificity, reproducibility, and clinical relevance.

Congenic mice are strains that have been developed through a specific breeding process to be genetically identical, except for a small region of interest (ROI) that has been introgressed from a donor strain. This is achieved by repeatedly backcrossing the donor ROI onto the genetic background of a recipient strain for many generations, followed by intercrossing within the resulting congenic line to ensure homozygosity of the ROI.

The goal of creating congenic mice is to study the effects of a specific gene or genomic region while minimizing the influence of other genetic differences between strains. This allows researchers to investigate the relationship between genotype and phenotype more accurately, which can be particularly useful in biomedical research for understanding complex traits, diseases, and potential therapeutic targets.

Autoimmune diseases are a group of disorders in which the immune system, which normally protects the body from foreign invaders like bacteria and viruses, mistakenly attacks the body's own cells and tissues. This results in inflammation and damage to various organs and tissues in the body.

In autoimmune diseases, the body produces autoantibodies that target its own proteins or cell receptors, leading to their destruction or malfunction. The exact cause of autoimmune diseases is not fully understood, but it is believed that a combination of genetic and environmental factors contribute to their development.

There are over 80 different types of autoimmune diseases, including rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, Graves' disease, psoriasis, and inflammatory bowel disease. Symptoms can vary widely depending on the specific autoimmune disease and the organs or tissues affected. Treatment typically involves managing symptoms and suppressing the immune system to prevent further damage.

IGA glomerulonephritis (also known as Berger's disease) is a type of glomerulonephritis, which is a condition characterized by inflammation of the glomeruli, the tiny filtering units in the kidneys. In IgA glomerulonephritis, the immune system produces an abnormal amount of IgA antibodies, which deposit in the glomeruli and cause inflammation. This can lead to symptoms such as blood in the urine, protein in the urine, and swelling in the legs and feet. In some cases, it can also lead to kidney failure. The exact cause of IgA glomerulonephritis is not known, but it is often associated with other conditions such as infections, autoimmune diseases, and certain medications.

A Severity of Illness Index is a measurement tool used in healthcare to assess the severity of a patient's condition and the risk of mortality or other adverse outcomes. These indices typically take into account various physiological and clinical variables, such as vital signs, laboratory values, and co-morbidities, to generate a score that reflects the patient's overall illness severity.

Examples of Severity of Illness Indices include the Acute Physiology and Chronic Health Evaluation (APACHE) system, the Simplified Acute Physiology Score (SAPS), and the Mortality Probability Model (MPM). These indices are often used in critical care settings to guide clinical decision-making, inform prognosis, and compare outcomes across different patient populations.

It is important to note that while these indices can provide valuable information about a patient's condition, they should not be used as the sole basis for clinical decision-making. Rather, they should be considered in conjunction with other factors, such as the patient's overall clinical presentation, treatment preferences, and goals of care.

Complement C4 is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Complement C4 is involved in the early stages of the complement activation cascade, where it helps to identify and tag foreign or abnormal cells for destruction by other components of the immune system.

Specifically, Complement C4 can be cleaved into two smaller proteins, C4a and C4b, during the complement activation process. C4b then binds to the surface of the target cell and helps to initiate the formation of the membrane attack complex (MAC), which creates a pore in the cell membrane and leads to lysis or destruction of the target cell.

Deficiencies or mutations in the Complement C4 gene can lead to various immune disorders, including certain forms of autoimmune diseases and susceptibility to certain infections.

Deoxyribonucleic acid (DNA) is the genetic material present in the cells of organisms where it is responsible for the storage and transmission of hereditary information. DNA is a long molecule that consists of two strands coiled together to form a double helix. Each strand is made up of a series of four nucleotide bases - adenine (A), guanine (G), cytosine (C), and thymine (T) - that are linked together by phosphate and sugar groups. The sequence of these bases along the length of the molecule encodes genetic information, with A always pairing with T and C always pairing with G. This base-pairing allows for the replication and transcription of DNA, which are essential processes in the functioning and reproduction of all living organisms.

Pulse therapy, in the context of drug treatment, refers to a therapeutic regimen where a medication is administered in large doses for a short period of time, followed by a break or "drug-free" interval before the next dose. This cycle is then repeated at regular intervals. The goal of pulse therapy is to achieve high concentrations of the drug in the body to maximize its therapeutic effect while minimizing overall exposure and potential side effects.

This approach is often used for drugs that have a long half-life or slow clearance, as it allows for periodic "washing out" of the drug from the body. Pulse therapy can also help reduce the risk of developing drug resistance in certain conditions like rheumatoid arthritis and tuberculosis. Common examples include pulse methotrexate for rheumatoid arthritis and intermittent preventive treatment with anti-malarial drugs.

It is important to note that the use of pulse therapy should be based on a thorough understanding of the drug's pharmacokinetics, therapeutic index, and potential adverse effects. Close monitoring of patients undergoing pulse therapy is essential to ensure safety and efficacy.

Hereditary nephritis is a genetic disorder that causes recurring inflammation of the kidneys' glomeruli, which are the tiny blood vessel clusters that filter waste from the blood. This condition is also known as hereditary glomerulonephritis.

The inherited form of nephritis is caused by mutations in specific genes, leading to abnormalities in the proteins responsible for maintaining the structural integrity and proper functioning of the glomeruli. As a result, affected individuals typically experience hematuria (blood in urine), proteinuria (protein in urine), hypertension (high blood pressure), and progressive kidney dysfunction that can ultimately lead to end-stage renal disease (ESRD).

There are different types of hereditary nephritis, such as Alport syndrome and thin basement membrane nephropathy. These conditions have distinct genetic causes, clinical presentations, and inheritance patterns. Early diagnosis and appropriate management can help slow the progression of kidney damage and improve long-term outcomes for affected individuals.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

Antiphospholipid antibodies are a type of autoantibody that targets and binds to certain proteins found in the blood that attach to phospholipids (a type of fat molecule). These antibodies are associated with an increased risk of developing antiphospholipid syndrome, a disorder characterized by abnormal blood clotting.

There are several types of antiphospholipid antibodies, including:

1. Lupus anticoagulant: This type of antiphospholipid antibody can interfere with blood clotting tests and may increase the risk of thrombosis (blood clots) in both arteries and veins.
2. Anticardiolipin antibodies: These antibodies target a specific phospholipid called cardiolipin, which is found in the inner membrane of mitochondria. High levels of anticardiolipin antibodies are associated with an increased risk of thrombosis and pregnancy complications such as recurrent miscarriage.
3. Anti-β2 glycoprotein I antibodies: These antibodies target a protein called β2 glycoprotein I, which binds to negatively charged phospholipids on the surface of cells. High levels of anti-β2 glycoprotein I antibodies are associated with an increased risk of thrombosis and pregnancy complications.

The exact mechanism by which antiphospholipid antibodies cause blood clotting is not fully understood, but it is thought to involve the activation of platelets, the inhibition of natural anticoagulants, and the promotion of inflammation. Antiphospholipid syndrome can be treated with medications that thin the blood or prevent clots from forming, such as aspirin, warfarin, or heparin.

Kidney disease, also known as nephropathy or renal disease, refers to any functional or structural damage to the kidneys that impairs their ability to filter blood, regulate electrolytes, produce hormones, and maintain fluid balance. This damage can result from a wide range of causes, including diabetes, hypertension, glomerulonephritis, polycystic kidney disease, lupus, infections, drugs, toxins, and congenital or inherited disorders.

Depending on the severity and progression of the kidney damage, kidney diseases can be classified into two main categories: acute kidney injury (AKI) and chronic kidney disease (CKD). AKI is a sudden and often reversible loss of kidney function that occurs over hours to days, while CKD is a progressive and irreversible decline in kidney function that develops over months or years.

Symptoms of kidney diseases may include edema, proteinuria, hematuria, hypertension, electrolyte imbalances, metabolic acidosis, anemia, and decreased urine output. Treatment options depend on the underlying cause and severity of the disease and may include medications, dietary modifications, dialysis, or kidney transplantation.

Combination drug therapy is a treatment approach that involves the use of multiple medications with different mechanisms of action to achieve better therapeutic outcomes. This approach is often used in the management of complex medical conditions such as cancer, HIV/AIDS, and cardiovascular diseases. The goal of combination drug therapy is to improve efficacy, reduce the risk of drug resistance, decrease the likelihood of adverse effects, and enhance the overall quality of life for patients.

In combining drugs, healthcare providers aim to target various pathways involved in the disease process, which may help to:

1. Increase the effectiveness of treatment by attacking the disease from multiple angles.
2. Decrease the dosage of individual medications, reducing the risk and severity of side effects.
3. Slow down or prevent the development of drug resistance, a common problem in chronic diseases like HIV/AIDS and cancer.
4. Improve patient compliance by simplifying dosing schedules and reducing pill burden.

Examples of combination drug therapy include:

1. Antiretroviral therapy (ART) for HIV treatment, which typically involves three or more drugs from different classes to suppress viral replication and prevent the development of drug resistance.
2. Chemotherapy regimens for cancer treatment, where multiple cytotoxic agents are used to target various stages of the cell cycle and reduce the likelihood of tumor cells developing resistance.
3. Cardiovascular disease management, which may involve combining medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and statins to control blood pressure, heart rate, fluid balance, and cholesterol levels.
4. Treatment of tuberculosis, which often involves a combination of several antibiotics to target different aspects of the bacterial life cycle and prevent the development of drug-resistant strains.

When prescribing combination drug therapy, healthcare providers must carefully consider factors such as potential drug interactions, dosing schedules, adverse effects, and contraindications to ensure safe and effective treatment. Regular monitoring of patients is essential to assess treatment response, manage side effects, and adjust the treatment plan as needed.

Hematuria is a medical term that refers to the presence of blood in urine. It can be visible to the naked eye, which is called gross hematuria, or detected only under a microscope, known as microscopic hematuria. The blood in urine may come from any site along the urinary tract, including the kidneys, ureters, bladder, or urethra. Hematuria can be a symptom of various medical conditions, such as urinary tract infections, kidney stones, kidney disease, or cancer of the urinary tract. It is essential to consult a healthcare professional if you notice blood in your urine to determine the underlying cause and receive appropriate treatment.

Plasmapheresis is a medical procedure where the liquid portion of the blood (plasma) is separated from the blood cells. The plasma, which may contain harmful substances such as antibodies or toxins, is then removed and replaced with fresh plasma or a plasma substitute. The remaining blood cells are mixed with the new plasma and returned to the body. This process is also known as therapeutic plasma exchange (TPE). It's used to treat various medical conditions including certain autoimmune diseases, poisonings, and neurological disorders.

Autoimmunity is a medical condition in which the body's immune system mistakenly attacks and destroys healthy tissues within the body. In normal function, the immune system recognizes and fights off foreign substances such as bacteria, viruses, and toxins. However, when autoimmunity occurs, the immune system identifies self-molecules or tissues as foreign and produces an immune response against them.

This misguided response can lead to chronic inflammation, tissue damage, and impaired organ function. Autoimmune diseases can affect various parts of the body, including the joints, skin, glands, muscles, and blood vessels. Some common examples of autoimmune diseases are rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, and Graves' disease.

The exact cause of autoimmunity is not fully understood, but it is believed to involve a combination of genetic, environmental, and lifestyle factors that trigger an abnormal immune response in susceptible individuals. Treatment for autoimmune diseases typically involves managing symptoms, reducing inflammation, and suppressing the immune system's overactive response using medications such as corticosteroids, immunosuppressants, and biologics.

Disease progression is the worsening or advancement of a medical condition over time. It refers to the natural course of a disease, including its development, the severity of symptoms and complications, and the impact on the patient's overall health and quality of life. Understanding disease progression is important for developing appropriate treatment plans, monitoring response to therapy, and predicting outcomes.

The rate of disease progression can vary widely depending on the type of medical condition, individual patient factors, and the effectiveness of treatment. Some diseases may progress rapidly over a short period of time, while others may progress more slowly over many years. In some cases, disease progression may be slowed or even halted with appropriate medical interventions, while in other cases, the progression may be inevitable and irreversible.

In clinical practice, healthcare providers closely monitor disease progression through regular assessments, imaging studies, and laboratory tests. This information is used to guide treatment decisions and adjust care plans as needed to optimize patient outcomes and improve quality of life.

The glomerular mesangium is a part of the nephron in the kidney. It is the region located in the middle of the glomerular tuft, where the capillary loops of the glomerulus are surrounded by a network of extracellular matrix and mesangial cells. These cells and matrix play an important role in maintaining the structure and function of the filtration barrier in the glomerulus, which helps to filter waste products from the blood.

The mesangial cells have contractile properties and can regulate the flow of blood through the capillaries by constricting or dilating the diameter of the glomerular capillary loops. They also play a role in immune responses, as they can phagocytize immune complexes and release cytokines and growth factors that modulate inflammation and tissue repair.

Abnormalities in the mesangium can lead to various kidney diseases, such as glomerulonephritis, mesangial proliferative glomerulonephritis, and diabetic nephropathy.

Chronic kidney failure, also known as chronic kidney disease (CKD) stage 5 or end-stage renal disease (ESRD), is a permanent loss of kidney function that occurs gradually over a period of months to years. It is defined as a glomerular filtration rate (GFR) of less than 15 ml/min, which means the kidneys are filtering waste and excess fluids at less than 15% of their normal capacity.

CKD can be caused by various underlying conditions such as diabetes, hypertension, glomerulonephritis, polycystic kidney disease, and recurrent kidney infections. Over time, the damage to the kidneys can lead to a buildup of waste products and fluids in the body, which can cause a range of symptoms including fatigue, weakness, shortness of breath, nausea, vomiting, and confusion.

Treatment for chronic kidney failure typically involves managing the underlying condition, making lifestyle changes such as following a healthy diet, and receiving supportive care such as dialysis or a kidney transplant to replace lost kidney function.

Thrombotic microangiopathies (TMAs) are a group of disorders characterized by the formation of blood clots in small blood vessels, causing damage to the end organs. This process leads to a constellation of clinical symptoms including thrombocytopenia (low platelet count), microangiopathic hemolytic anemia (breakdown of red blood cells leading to anemia), and organ dysfunction such as renal failure, neurological impairment, or cardiac involvement.

TMAs can be primary or secondary. Primary TMAs are caused by genetic mutations affecting the complement system, coagulation cascade, or other regulatory proteins involved in vascular homeostasis. Examples of primary TMAs include atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and complement-mediated TMA.

Secondary TMAs are caused by various underlying conditions or exposures, such as infections, autoimmune diseases, malignancies, drugs, pregnancy-related complications, or other systemic disorders. The pathogenesis of secondary TMAs is often multifactorial and may involve endothelial injury, complement activation, and platelet aggregation.

The diagnosis of TMAs requires a combination of clinical, laboratory, and sometimes histopathological findings. Treatment depends on the underlying cause and may include supportive care, plasma exchange, immunosuppressive therapy, or targeted therapies such as complement inhibitors.

Tripterygium is not a medical term itself, but it refers to a genus of plants also known as thunder god vine. The root and bark extracts of this plant have been used in traditional Chinese medicine for various inflammatory and autoimmune conditions. Some compounds derived from Tripterygium species, such as triptolide and celastrol, have attracted interest in modern medical research due to their potential immunosuppressive and anti-inflammatory properties. However, the use of Tripterygium extracts is associated with several side effects, and further studies are required to establish their safety and efficacy for therapeutic purposes.

The Fluorescent Antibody Technique (FAT) is a type of immunofluorescence assay used in laboratory medicine and pathology for the detection and localization of specific antigens or antibodies in tissues, cells, or microorganisms. In this technique, a fluorescein-labeled antibody is used to selectively bind to the target antigen or antibody, forming an immune complex. When excited by light of a specific wavelength, the fluorescein label emits light at a longer wavelength, typically visualized as green fluorescence under a fluorescence microscope.

The FAT is widely used in diagnostic microbiology for the identification and characterization of various bacteria, viruses, fungi, and parasites. It has also been applied in the diagnosis of autoimmune diseases and certain cancers by detecting specific antibodies or antigens in patient samples. The main advantage of FAT is its high sensitivity and specificity, allowing for accurate detection and differentiation of various pathogens and disease markers. However, it requires specialized equipment and trained personnel to perform and interpret the results.

Anticardiolipin antibodies are a type of autoantibody that targets and binds to cardiolipin, a phospholipid component found in the inner mitochondrial membrane of cells. These antibodies are clinically significant because they have been associated with a variety of autoimmune disorders, including antiphospholipid syndrome (APS).

APS is a condition characterized by recurrent blood clots, pregnancy losses, and thrombocytopenia (low platelet count). Anticardiolipin antibodies are one of the three main types of autoantibodies found in APS, along with lupus anticoagulant and anti-β2 glycoprotein I antibodies.

The presence of high levels of anticardiolipin antibodies in the blood can lead to abnormal blood clotting, which can cause serious complications such as deep vein thrombosis, pulmonary embolism, and stroke. Anticardiolipin antibodies can also contribute to pregnancy losses by causing placental insufficiency or abnormal blood clotting in the placenta.

Anticardiolipin antibodies are typically detected through a blood test that measures their levels in the serum. A positive result is usually confirmed with a second test performed at least 12 weeks later to establish persistence. Treatment for anticardiolipin antibody-related disorders typically involves anticoagulation therapy to prevent blood clots and other complications.

Interstitial nephritis is a condition characterized by inflammation in the interstitium (the tissue between the kidney tubules) of one or both kidneys. This inflammation can be caused by various factors, including infections, autoimmune disorders, medications, and exposure to certain toxins.

The inflammation may lead to symptoms such as hematuria (blood in the urine), proteinuria (protein in the urine), decreased urine output, and kidney dysfunction. In some cases, interstitial nephritis can progress to chronic kidney disease or even end-stage renal failure if left untreated.

The diagnosis of interstitial nephritis typically involves a combination of medical history, physical examination, laboratory tests (such as urinalysis and blood tests), and imaging studies (such as ultrasound or CT scan). A kidney biopsy may also be performed to confirm the diagnosis and assess the severity of the inflammation.

Treatment for interstitial nephritis depends on the underlying cause, but may include corticosteroids, immunosuppressive medications, or discontinuation of any offending medications. In some cases, supportive care such as dialysis may be necessary to manage kidney dysfunction until the inflammation resolves.

B-lymphocytes, also known as B-cells, are a type of white blood cell that plays a key role in the immune system's response to infection. They are responsible for producing antibodies, which are proteins that help to neutralize or destroy pathogens such as bacteria and viruses.

When a B-lymphocyte encounters a pathogen, it becomes activated and begins to divide and differentiate into plasma cells, which produce and secrete large amounts of antibodies specific to the antigens on the surface of the pathogen. These antibodies bind to the pathogen, marking it for destruction by other immune cells such as neutrophils and macrophages.

B-lymphocytes also have a role in presenting antigens to T-lymphocytes, another type of white blood cell involved in the immune response. This helps to stimulate the activation and proliferation of T-lymphocytes, which can then go on to destroy infected cells or help to coordinate the overall immune response.

Overall, B-lymphocytes are an essential part of the adaptive immune system, providing long-lasting immunity to previously encountered pathogens and helping to protect against future infections.

Cryoglobulins are immunoglobulins (a type of antibody) that precipitate or become insoluble at reduced temperatures, typically below 37°C (98.6°F), and re-dissolve when rewarmed. They can be found in various clinical conditions such as infections, inflammatory diseases, and lymphoproliferative disorders.

The presence of cryoglobulins in the blood can lead to a variety of symptoms, including purpura (a type of skin rash), arthralgias (joint pain), neuropathy (nerve damage), and glomerulonephritis (kidney inflammation). The diagnosis of cryoglobulinemia is made by detecting the presence of cryoglobulins in the serum, which requires special handling and processing of the blood sample. Treatment of cryoglobulinemia depends on the underlying cause and may include medications such as corticosteroids, immunosuppressive agents, or targeted therapies.

Nephrotic syndrome is a group of symptoms that indicate kidney damage, specifically damage to the glomeruli—the tiny blood vessel clusters in the kidneys that filter waste and excess fluids from the blood. The main features of nephrotic syndrome are:

1. Proteinuria (excess protein in urine): Large amounts of a protein called albumin leak into the urine due to damaged glomeruli, which can't properly filter proteins. This leads to low levels of albumin in the blood, causing fluid buildup and swelling.
2. Hypoalbuminemia (low blood albumin levels): As albumin leaks into the urine, the concentration of albumin in the blood decreases, leading to hypoalbuminemia. This can cause edema (swelling), particularly in the legs, ankles, and feet.
3. Edema (fluid retention and swelling): With low levels of albumin in the blood, fluids move into the surrounding tissues, causing swelling or puffiness. The swelling is most noticeable around the eyes, face, hands, feet, and abdomen.
4. Hyperlipidemia (high lipid/cholesterol levels): The kidneys play a role in regulating lipid metabolism. Damage to the glomeruli can lead to increased lipid production and high cholesterol levels in the blood.

Nephrotic syndrome can result from various underlying kidney diseases, such as minimal change disease, membranous nephropathy, or focal segmental glomerulosclerosis. Treatment depends on the underlying cause and may include medications to control inflammation, manage high blood pressure, and reduce proteinuria. In some cases, dietary modifications and lifestyle changes are also recommended.

Vasculitis is a group of disorders characterized by inflammation of the blood vessels, which can cause changes in the vessel walls including thickening, narrowing, or weakening. These changes can restrict blood flow, leading to organ and tissue damage. The specific symptoms and severity of vasculitis depend on the size and location of the affected blood vessels and the extent of inflammation. Vasculitis can affect any organ system in the body, and its causes can vary, including infections, autoimmune disorders, or exposure to certain medications or chemicals.

The complement system is a group of proteins found in the blood and on the surface of cells that when activated, work together to help eliminate pathogens such as bacteria, viruses, and fungi from the body. The proteins are normally inactive in the bloodstream. When they encounter an invading microorganism or foreign substance, a series of reactions take place leading to the activation of the complement system. Activation results in the production of effector molecules that can punch holes in the cell membranes of pathogens, recruit and activate immune cells, and help remove debris and dead cells from the body.

There are three main pathways that can lead to complement activation: the classical pathway, the lectin pathway, and the alternative pathway. Each pathway involves a series of proteins that work together in a cascade-like manner to amplify the response and generate effector molecules. The three main effector molecules produced by the complement system are C3b, C4b, and C5b. These molecules can bind to the surface of pathogens, marking them for destruction by other immune cells.

Complement proteins also play a role in the regulation of the immune response. They help to prevent excessive activation of the complement system, which could damage host tissues. Dysregulation of the complement system has been implicated in a number of diseases, including autoimmune disorders and inflammatory conditions.

In summary, Complement System Proteins are a group of proteins that play a crucial role in the immune response by helping to eliminate pathogens and regulate the immune response. They can be activated through three different pathways, leading to the production of effector molecules that mark pathogens for destruction. Dysregulation of the complement system has been linked to various diseases.

Inbred strains of mice are defined as lines of mice that have been brother-sister mated for at least 20 consecutive generations. This results in a high degree of homozygosity, where the mice of an inbred strain are genetically identical to one another, with the exception of spontaneous mutations.

Inbred strains of mice are widely used in biomedical research due to their genetic uniformity and stability, which makes them useful for studying the genetic basis of various traits, diseases, and biological processes. They also provide a consistent and reproducible experimental system, as compared to outbred or genetically heterogeneous populations.

Some commonly used inbred strains of mice include C57BL/6J, BALB/cByJ, DBA/2J, and 129SvEv. Each strain has its own unique genetic background and phenotypic characteristics, which can influence the results of experiments. Therefore, it is important to choose the appropriate inbred strain for a given research question.

Mesangial cells are specialized cells that are found in the mesangium, which is the middle layer of the glomerulus in the kidney. The glomerulus is a network of capillaries where blood filtration occurs. Mesangial cells play an important role in maintaining the structure and function of the glomerulus. They help regulate the size of the filtration slits between the capillary endothelial cells and the podocytes (specialized epithelial cells) by contracting and relaxing, similar to smooth muscle cells. Additionally, mesangial cells can phagocytize immune complexes and other debris in the glomerulus, contributing to the body's immune response. They also produce extracellular matrix components that provide structural support for the glomerulus. Mesangial cell dysfunction or injury can contribute to kidney diseases such as glomerulonephritis and diabetic nephropathy.

Hypoalbuminemia is a medical condition characterized by having lower than normal levels of albumin in the blood. Albumin is a type of protein produced by the liver, and it plays a crucial role in maintaining oncotic pressure (the force that keeps fluid inside blood vessels) and transporting various substances throughout the body.

A serum albumin level below 3.5 g/dL (grams per deciliter) is generally considered hypoalbuminemia, although some laboratories may define it as a level below 3.4 g/dL or even lower. This condition can be caused by various factors, including liver disease, malnutrition, kidney disease, inflammation, and protein-losing enteropathy (a disorder that causes excessive loss of protein in the gastrointestinal tract).

Hypoalbuminemia is often associated with poorer clinical outcomes in several medical conditions, such as increased risk of infection, longer hospital stays, and higher mortality rates. It's essential to identify and address the underlying cause of hypoalbuminemia for appropriate treatment and improved patient outcomes.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Hydroxychloroquine is an antimalarial and autoimmune disease medication. It's primarily used to prevent or treat malaria, a disease caused by parasites that enter the body through the bites of infected mosquitoes. It works by killing the malaria parasite in the red blood cells of the human body.

In addition, hydroxychloroquine is also used to treat autoimmune diseases such as rheumatoid arthritis and lupus. In these conditions, the body's immune system mistakenly attacks healthy tissues, causing inflammation and damage. Hydroxychloroquine helps to regulate the immune system and reduce inflammation.

It is important to note that while hydroxychloroquine has been studied as a potential treatment for COVID-19, current evidence does not support its use outside of a clinical trial setting due to lack of efficacy and potential for harm.

Lipoid nephrosis is a historical term for a kidney disorder now more commonly referred to as minimal change disease (MCD). It is a type of glomerulonephritis which is characterized by the loss of proteins in the urine (proteinuria) due to damage to the glomeruli, the tiny filtering units within the kidneys.

The term "lipoid" refers to the presence of lipids or fats in the glomeruli, which can be observed under a microscope. However, it's worth noting that not all cases of MCD involve lipid accumulation in the glomeruli.

MCD is typically idiopathic, meaning its cause is unknown, but it can also occur as a secondary condition related to other medical disorders such as allergies, infections, or medications. It primarily affects children, but can also occur in adults. Treatment usually involves corticosteroids and other immunosuppressive therapies to control proteinuria and prevent kidney damage.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

An Enzyme-Linked Immunosorbent Assay (ELISA) is a type of analytical biochemistry assay used to detect and quantify the presence of a substance, typically a protein or peptide, in a liquid sample. It takes its name from the enzyme-linked antibodies used in the assay.

In an ELISA, the sample is added to a well containing a surface that has been treated to capture the target substance. If the target substance is present in the sample, it will bind to the surface. Next, an enzyme-linked antibody specific to the target substance is added. This antibody will bind to the captured target substance if it is present. After washing away any unbound material, a substrate for the enzyme is added. If the enzyme is present due to its linkage to the antibody, it will catalyze a reaction that produces a detectable signal, such as a color change or fluorescence. The intensity of this signal is proportional to the amount of target substance present in the sample, allowing for quantification.

ELISAs are widely used in research and clinical settings to detect and measure various substances, including hormones, viruses, and bacteria. They offer high sensitivity, specificity, and reproducibility, making them a reliable choice for many applications.

Prednisone is a synthetic glucocorticoid, which is a type of corticosteroid hormone. It is primarily used to reduce inflammation in various conditions such as asthma, allergies, arthritis, and autoimmune disorders. Prednisone works by mimicking the effects of natural hormones produced by the adrenal glands, suppressing the immune system's response and reducing the release of substances that cause inflammation.

It is available in oral tablet form and is typically prescribed to be taken at specific times during the day, depending on the condition being treated. Common side effects of prednisone include increased appetite, weight gain, mood changes, insomnia, and easy bruising. Long-term use or high doses can lead to more serious side effects such as osteoporosis, diabetes, cataracts, and increased susceptibility to infections.

Healthcare providers closely monitor patients taking prednisone for extended periods to minimize the risk of adverse effects. It is essential to follow the prescribed dosage regimen and not discontinue the medication abruptly without medical supervision, as this can lead to withdrawal symptoms or a rebound of the underlying condition.

The Fluorescent Antibody Technique (FAT), Direct is a type of immunofluorescence assay used in laboratory diagnostic tests. It is a method for identifying and locating specific antigens in cells or tissues by using fluorescent-labeled antibodies that directly bind to the target antigen.

In this technique, a sample (such as a tissue section or cell smear) is prepared and then treated with a fluorescently labeled primary antibody that specifically binds to the antigen of interest. After washing away unbound antibodies, the sample is examined under a fluorescence microscope. If the antigen is present in the sample, it will be visible as distinct areas of fluorescence, allowing for the direct visualization and localization of the antigen within the cells or tissues.

Direct FAT is commonly used in diagnostic laboratories to identify and diagnose various infectious diseases, including bacterial, viral, and fungal infections. It can also be used to detect specific proteins or antigens in research and clinical settings.

Diagnostic techniques in urology are methods used to identify and diagnose various urological conditions affecting the urinary tract and male reproductive system. These techniques include:

1. Urinalysis: A laboratory examination of a urine sample to detect abnormalities such as infection, kidney stones, or other underlying medical conditions.
2. Urine Culture: A test used to identify and grow bacteria from the urine to determine the type of bacterial infection present in the urinary tract.
3. Imaging Studies: Various imaging techniques such as X-rays, ultrasound, CT scans, and MRI scans are used to visualize the internal structures of the urinary tract and identify any abnormalities.
4. Cystoscopy: A procedure that involves inserting a thin tube with a camera into the bladder through the urethra to examine the bladder and urethra for signs of disease or abnormality.
5. Urodynamics: A series of tests used to evaluate bladder function, including measuring bladder pressure and urine flow rate.
6. Biopsy: The removal and examination of tissue from the urinary tract or male reproductive system to diagnose conditions such as cancer.
7. Prostate-Specific Antigen (PSA) Test: A blood test used to screen for prostate cancer by measuring the level of PSA, a protein produced by the prostate gland.
8. Voiding Diary: A record of urinary habits, including the frequency and volume of urination, that can help diagnose conditions such as overactive bladder or urinary incontinence.

"Lupus Nephritis". www.niddk.nih.gov. Retrieved 2015-10-31. "Lupus nephritis: MedlinePlus Medical Encyclopedia". www.nlm.nih.gov ... Lupus nephritis affects approximately 3 out of 10,000 people. The pathophysiology of lupus nephritis has autoimmunity ... "Lupus Nephritis - National Library of Medicine". PubMed Health. Retrieved 2015-11-03. Salgado, Alberto (2012). "Lupus Nephritis ... concomitant lupus nephritis is associated with a worse overall prognosis. 10-30% of people with lupus nephritis progress to ...
... lupus nephritis) is 28.4 years old. Nephrotic syndrome Bright's Disease Goodpasture syndrome Lupus nephritis " ... Lupus nephritis is inflammation of the kidney caused by systemic lupus erythematosus (SLE), a disease of the immune system. ... The diagnosis depends on the cause of the nephritis, and in the case of lupus nephritis, blood tests, X-rays and an ultrasound ... "Lupus Nephritis". www.niddk.nih.gov. Archived from the original on 2017-01-04. Retrieved 2015-06-14. "Nephritis Symptoms". ...
For example, systemic lupus erythematosus with severe lupus nephritis may respond to pulsed cyclophosphamide. Cyclophosphamide ... Lupus nephritis". Annals of Internal Medicine. 106 (1): 79-94. doi:10.7326/0003-4819-106-1-79. PMID 3789582. Periti P, Mazzei T ... reduces bladder exposure to acrolein and has equal efficacy to daily treatment in the management of lupus nephritis. ... "Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and ...
... lupus nephritis, IgA nephropathy) Secondary diagnosis (i.e., ATN, interstitial nephritis, thrombotic microangiopathy) Ancillary ... Microscopic haematuria with or without proteinuria may be seen in Class II Lupus nephritis. Hypertension, nephrotic syndrome, ... Mesangial proliferative glomerulonephritis of Lupus nephritis, Class II is also noted by mesangial hypercellularity and matrix ... Lupus Nephritis. OUP Oxford. pp. 174-177. ISBN 9780199568055. Little, Mark A.; Dorman, Anthony; Gill, Denis; Walshe, J. Joseph ...
The most common associated disease of DPGN is severe systemic lupus erythematosus(SLE). Specifically, Lupus nephritis class IV ... "Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study". Lupus. 13 ... Korbet, Stephen M.; Schwartz, Melvin M.; Evans, Joni; Lewis, Edmund J. (2007-01-01). "Severe Lupus Nephritis: Racial ... and management of lupus nephritis". Arthritis Care & Research. 64 (6): 797-808. doi:10.1002/acr.21664. PMC 3437757. PMID ...
... lupus nephritis remains a major cause of morbidity and mortality in people with relapsing or refractory lupus nephritis. ... "Lupus nephritis: a critical review". Autoimmunity Reviews. 12 (2): 174-194. doi:10.1016/j.autrev.2012.08.018. ISSN 1873-0183. ... Nephritis is an inflammatory kidney disease and has several types according to the location of the inflammation. Inflammation ... Nephritis and nephrosis can give rise to nephritic syndrome and nephrotic syndrome respectively. Kidney disease usually causes ...
"TNIP1/ABIN1 and lupus nephritis: review". Lupus Science & Medicine. 7 (1): e000437. doi:10.1136/lupus-2020-000437. PMC 7597513 ... Systemic Lupus Erythematosus Type-1 autoimmune hepatitis Lupus nephritis TNIP1 dysfunction or deficiency contributes to ... UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus". Nature Genetics. 41 (11): 1228-1233. doi:10.1038/ng.468. PMC ... "Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus ...
"Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis ...
"Lupus and Kidney Disease (Lupus Nephritis) , NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. ... Systemic Lupus Erythematous (SLE): An autoimmune disease in which the body makes antibodies that deposit harmful ...
CD11b plays a protective role during SLE and lupus nephritis owing to its anti-inflammatory properties. Lupus nephritis is ... Some examples would be systemic lupus erythematosus (SLE), lupus nephritis and certain types of cancer. Genome Wide Association ... Khan SQ, Khan I, Gupta V (2018-03-15). "CD11b Activity Modulates Pathogenesis of Lupus Nephritis". Frontiers in Medicine. 5: 52 ... and lupus nephritis (a complication usually occurring along with SLE). These SNPs are: rs1143679 (R77H), rs1143678 (P1146S), ...
The disease can also cause lupus nephritis. Sarcoidosis: This disease does not usually affect the kidney but, on occasions, the ... Systemic lupus erythematosus: this autoimmune disease can affect a number of organs, among them the kidney, due to the deposit ... It may also occur as a complication of diabetes or lupus. The underlying mechanism typically involves damage to the glomeruli ... May have features of the underlying cause, such as the rash associated with systemic lupus erythematosus, or the neuropathy ...
Lupus nephritis was the most common manifestation. Of live births, approximately one third are delivered prematurely. Lupus ... "Planning a pregnancy when you have lupus , Lupus Foundation of America". www.lupus.org. Retrieved 2020-10-25. Systemic Lupus ... Neonatal lupus is the occurrence of lupus symptoms in an infant born from a mother with lupus, most commonly presenting with a ... Updated: Sep 20, 2010 "Planning a pregnancy when you have lupus , Lupus Foundation of America". www.lupus.org. Retrieved 2020- ...
Parikh SV, Almaani S, Brodsky S, Rovin BH (August 2020). "Update on Lupus Nephritis: Core Curriculum 2020". American Journal of ... Chemotherapy and radiation treatments for cancer and autoimmunity conditions like Lupus and Multiple Sclerosis have the ability ...
In Lupus Nephritis, a common manifestation of SLE, patients are often prescribed methylprednisolone concomitantly with ... Chan TM (January 2015). "Treatment of severe lupus nephritis: the new horizon". Nature Reviews. Nephrology. 11 (1): 46-61. doi: ... Nephrology: nephrotic syndrome, idiopathic type or secondary to lupus nephritis. Neurology: multiple sclerosis. Ophthalmology: ... Kaul A, Gordon C, Crow M, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G (2016). "Systemic lupus ...
They are highly diagnostic of systemic lupus erythematosus (SLE) and are implicated in the pathogenesis of lupus nephritis. The ... Mortensen ES, Fenton KA, Rekvig OP (February 2008). "Lupus nephritis: the central role of nucleosomes revealed". Am. J. Pathol ... Berden JH (August 2003). "Lupus nephritis: consequence of disturbed removal of apoptotic cells?". Neth J Med. 61 (8): 233-8. ... Yung S, Chan TM (February 2008). "Anti-DNA antibodies in the pathogenesis of lupus nephritis--the emerging mechanisms". ...
Cyclophosphamide is sometimes used to treat lupus nephritis, a common symptom of systemic lupus erythematosus. Dexamethasone ... Ntali S, Bertsias G, Boumpas DT (June 2011). "Cyclophosphamide and lupus nephritis: when, how, for how long?". Clinical Reviews ... systemic lupus erythematosus, multiple sclerosis, vasculitis and many others. There are a number of strategies in the ...
"Cellular and Molecular Mechanisms of Autoimmunity and Lupus Nephritis". International Review of Cell and Molecular Biology. ...
... miR-198 and miR-146a expression in lupus nephritis". Nephrology. 17 (4): 346-51. doi:10.1111/j.1440-1797.2012.01573.x. PMID ... "Identification of unique microRNA signature associated with lupus nephritis". PLOS ONE. 5 (5): e10344. Bibcode:2010PLoSO... ...
Walsh proposed that mycophenolate should be considered as a first-line induction therapy for treatment of lupus nephritis in ... Its increasing application in treating lupus nephritis has demonstrated more frequent complete response and less frequent ... November 2011). "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis". The New England Journal of ... "Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis". Clinical Journal of the ...
In systemic lupus erythematosus ATA are associated with nephritis. Increases in ATA+ in scleroderma and SLE are associated with ... "Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis". Clinical Rheumatology. 25 (4 ...
miR-638 has been implicated in the pathogenesis of lupus nephritis (LN), with intra-renal expression levels differing between ... miR-198 and miR-146a expression in lupus nephritis". Nephrology. 17 (4): 346-51. doi:10.1111/j.1440-1797.2012.01573.x. PMID ... "Identification of unique microRNA signature associated with lupus nephritis". PLOS ONE. 5 (5): e10344. Bibcode:2010PLoSO... ... normal and lupus nephritis patients. The degree of difference in expression levels further correlates with the degree of ...
It is predominantly found in younger, female patients, and indeed 1/3 of patients with class V lupus nephritis are EXT positive ... A less common target antigen in lupus nephritis is NCAM1. Semaphorin3B predominates in children, esp ...
"Application of arsenic trioxide for the treatment of lupus nephritis". Chinese Medical Association. Archived from the original ...
May 2010). "Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis". Proceedings of the ... "BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis". Journal of ... Kavai M, Szegedi G (August 2007). "Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus". ... May 2016). "Apoptotic Debris Accumulates on Hematopoietic Cells and Promotes Disease in Murine and Human Systemic Lupus ...
... and lupus nephritis. Mutations in the gene promoter for the Atg5 gene have been associated with sporadic Parkinson's disease ... "Detecting Genetic Associations between ATG5 and Lupus Nephritis by trans-eQTL". Journal of Immunology Research. 2015: 153132. ... Polymorphisms within the Atg5 gene have been associated with Behçet's disease, systemic lupus erythematosus, ... "Rare Variants of ATG5 Are Likely to Be Associated With Chinese Patients With Systemic Lupus Erythematosus". Medicine. 94 (22): ...
Lupus nephritis is a common form of glomerular nephritis occurring in patients with systemic lupus nephritis. Lupus nephritis ... It is a significant risk factor for morbidity and mortality in systemic lupus erythematosus. The management of lupus nephritis ... Since lupus nephritis is a serious, disabling, and possibly life-threating illness, it is not surprising to see mortality in ... Guidelines for managing lupus nephritis are provided by the Kidney Disease Improving Global Outcomes (KDIGO) and the European ...
"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis". Proc Natl Acad Sci U S A. 107 (21 ... Lachmann PJ (2003). "Lupus and desoxyribonuclease". Lupus. 12 (3): 202-6. doi:10.1191/0961203303lu357xx. PMID 12708782. S2CID ... Mutations in this gene, as well as factor inactivating its enzyme product, have been associated with systemic lupus ... 2001). "Mutation of DNASE1 in people with systemic lupus erythematosus". Nat. Genet. 28 (4): 313-4. doi:10.1038/91070. PMID ...
"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis". Proceedings of the National ...
January 2011). "Intrarenal production of B-cell survival factors in human lupus nephritis". Modern Pathology. 24 (1): 98-107. ... lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjögren syndrome, Graves' disease, and Hashimoto's thyroiditis. ... Blisibimod is currently being tested in a Phase 3 study, CHABLIS-SC1, for systemic lupus erythematosus, and a Phase 2 study, ... "Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of ...
"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis". Proc Natl Acad Sci U S A. 107 (21 ... extracellular exposure of histone complexes could play a role during the development of autoimmune diseases like systemic lupus ...
"Lupus Nephritis". www.niddk.nih.gov. Retrieved 2015-10-31. "Lupus nephritis: MedlinePlus Medical Encyclopedia". www.nlm.nih.gov ... Lupus nephritis affects approximately 3 out of 10,000 people. The pathophysiology of lupus nephritis has autoimmunity ... "Lupus Nephritis - National Library of Medicine". PubMed Health. Retrieved 2015-11-03. Salgado, Alberto (2012). "Lupus Nephritis ... concomitant lupus nephritis is associated with a worse overall prognosis. 10-30% of people with lupus nephritis progress to ...
Lupus nephritis, which is a kidney disorder, is a complication of systemic lupus erythematosus. ... Lupus nephritis, which is a kidney disorder, is a complication of systemic lupus erythematosus. ... Lupus nephritis, which is a kidney disorder, is a complication of systemic lupus erythematosus. ... How well you do depends on the specific form of lupus nephritis. You may have flare-ups, and then times when you do not have ...
Lupus nephritis is histologically evident in most patients with SLE, even those without cl... ... one of the most serious manifestations of systemic lupus erythematosus (SLE), usually arises within 5 years of diagnosis; ... Asymptomatic lupus nephritis * During regular follow-up, laboratory abnormalities suggesting active lupus nephritis include ... Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose ...
SLE or lupus), up to 60% of adult patients and 80% of children will develop lupus nephritis (LN), and up to half of those will ... In the ever-perilous autoimmune disease world of systemic lupus erythematosus ( ... to learn how to read and classify lupus nephritis biopsy slides.. The goal of using AI to classify lupus nephritis in an ... Lupus, Lupus Erythematosus, Machine Learning, Nephritis, Renal disease, Systemic Lupus Erythematosus ...
Otsukas lupus nephritis drug Lupkynis backed for NHS use Patients in England and Wales with active lupus nephritis will soon ... Otsuka, Aurinia claim EU okay for oral lupus nephritis drug Aurinia Pharma and partner Otsuka have secured approval in the EU ... Aurinia scores big win in lupus nephritis trial Small biopharma company Aurinia has released promising results of its candidate ... for lupus nephritis (LN) claiming it to be the first ever to show efficacy against the condition. ...
... recovery and follow-up care for Lupus nephritis. ... Learn about Lupus nephritis, find a doctor, complications, ... Lupus nephritis, which is a kidney disorder, is a complication of systemic lupus erythematosus. ... How well you do depends on the specific form of lupus nephritis. You may have flare-ups, and then times when you do not have ... Lupus nephritis. In: Feehally J, Floege J, Tonelli M, Johnson RJ, eds. Comprehensive Clinical Nephrology. 6th ed. Philadelphia ...
Your Lupus Nephritis Awareness Kit which includes an informative brochure, disease awareness bracelets, and USB drive with ... Free Lupus Nephritis Awareness Kit Your Lupus Nephritis Awareness Kit which includes an informative brochure, disease awareness ... and USB drive with materials to help you better understand and manage lupus nephritis. ...
Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is ineffective and often toxic. To ... we analyzed kidney samples from patients with lupus nephritis and from healthy control subjects using single-cell RNA ...
Associate Professor of Medicine (Rheumatology); Director of Education and Training, Rheumatology; Director Yale Lupus Program ...
Proliferation signal inhibitors warrants further investigation as an alternative immunosuppressive treatment in lupus nephritis ... Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience Nephrology (Carlton). 2012 Nov;17(8 ... Methods: This is a retrospective study on patients with proliferative lupus nephritis who had received PSI treatment. ... We report here our experience of using PSI treatment in seven patients with severe proliferative lupus nephritis. ...
... are at significantly increased risk of pregnancy complications compared to women with lupus without LN. ... New study findings show women with lupus nephritis (LN) - especially those with active LN - ... New study findings show women with lupus nephritis (LN, lupus-related kidney disease) - especially those with active LN - are ... Update: KYV-101 for Treatment of Refractory Lupus Nephritis Appears Safe for First U.S. study participant After 28-Days of ...
The medical records of patients receiving cyclophosphamide for lupus nephritis between 1987 and 1993 at the New York University ... for Joint Diseases Lupus Study Group Institutions were retrospectively reviewed. We identified 45 patients (38 female, seven ... efficacy in steroid unresponsive lupus nephritis Lupus. 1995 Apr;4(2):104-8. doi: 10.1177/096120339500400205. ... The medical records of patients receiving cyclophosphamide for lupus nephritis between 1987 and 1993 at the New York University ...
Lupus nephritis is a severe disease manifestation of SLE heterogeneity. Patients with lupus nephritis are at high-risk of ... regulatory T cells on lupus nephritis patient samples as well as in mice with lupus nephritis. ... Lupus nephritis affects approximately half of lupus patients and can shorten life expectancy. Dr. Ooi has pioneered the ... 3. Treat disease in vivo using a humanised model of lupus nephritis. We have established a new humanised mouse model of lupus ...
Kidney inflammation caused by Systemic Lupus Erythematosus (SLE) is referred to as lupus nephritis or LN, and it is estimated ... Small biopharma company Aurinia has released promising results of its candidate for lupus nephritis (LN) claiming it to be the ...
Many nephrologists, myself included, are eager to find alternatives to cyclophosphamide in the management of lupus nephritis. ... "The indication for hydroxychloroquine in lupus is lupus," added Dr. Wofsy, professor of medicine and microbiology/immunology at ... may be superior and less toxic than cyclophosphamide in the management of lupus nephritis. In the May issue of the Journal of ... This is a great post on chloroquine in lupus. It appears as below on Skin and Allergy News. A great and promising read:. ...
Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis ... About Lupus Nephritis (LN). Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), more commonly ... Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis ... Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis ...
Patients with proliferative lupus nephritis were positive with dsDNA-loaded nucleosomes in 86%, with DNA in 66% and with ... Patients with proliferative lupus nephritis were positive with dsDNA-loaded nucleosomes in 86%, with DNA in 66% and with ... Patients with proliferative lupus nephritis were positive with dsDNA-loaded nucleosomes in 86%, with DNA in 66% and with ... Patients with proliferative lupus nephritis were positive with dsDNA-loaded nucleosomes in 86%, with DNA in 66% and with ...
In addition, genes associated with lupus nephritis in a prior genome-wide association study were not differentially methylated ... These findings have not been identified in genetic studies of lupus nephritis, suggesting that epigenome-wide association ... Pathway analyses were used to identify biological processes associated with lupus nephritis.ResultsWe identified differential ... 80 of whom had lupus nephritis, using the Illumina HumanMethylation450 BeadChip. Multivariable linear regression adjusting for ...
This was an important review for our centre, since our patients presented an elevated proportion of Lupus Nephritis, at a very ... The aim of this project was to understand the prevalence, morbidity and outcome associated with lupus nephritis at our auto- ... Among all patients, 21.2% (n=29) had clinical and histologic diagnostic criteria for lupus nephritis, with mean age at ... Systemic lupus erythematosus (SLE) is a clinically heterogeneous multi-system disease, that is characterised by the presence of ...
... is a condition in which the the kidneys become inflamed as a result of systemic lupus erythematosus. Lupus ... commonly known as lupus, is a disease in which the the immune system produces proteins that attack the body and cause damage to ... nephritis can lead to impaired kidney function or, in extreme cases, kidney failure. ... A kidney biopsy may also be performed to diagnose lupus nephritis.. Treatment of Lupus Nephritis. Lupus nephritis is typically ...
Propecia online pharmacy imuran for lupus nephritis. A Little imuran for lupus nephritis ... 4 Mar 2015 imuran for lupus nephritis. Levitra Consumer Information. Costco Pharmacy. Viagra No Rx . €0 imuran for lupus ... Imuran for lupus nephritis. Betnovate c skin cream india Published Date: 2019-10-13 Rhine inc india viagra ... Cela a réveillé un vif débat sur la vente en ligne des médicaments imuran for lupus nephritis. Tienda en línea de la píldora, ...
Therapeutic targeting of macrophages in lupus nephritis. Samantha A. Chalmers, Violeta Chitu, Meera Ramanujam, Chaim Putterman ... Dive into the research topics of Therapeutic targeting of macrophages in lupus nephritis. Together they form a unique ...
... . Cialis works faster than other ED drugs . Fast delivery by courier or airmail imuran for lupus ... Imuran for lupus nephritis. Generic lexapro fast deliveryAtarax medicine is used forGeneric lexapro fast delivery ... Cialis barato Canadá en línea la compra paypal compre il . Buy Viagra In Bulk imuran for lupus nephritis. Cialis is indicated ... Viagra Pharmacie Online imuran for lupus nephritis. good canadian pharmacy to buy viagra. is a green pharmacie light beckoning ...
Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis. ... Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. * Authors: Appel GB, Contreras G, ... Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective ... Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.. ...
keywords = "Systemic lupus erythematosus, Lupus nephritis, Acute renal failure, Terminal renal failure, Dialysis, Differential ... Pediatric lupus nephritis presenting with terminal renal failure. Martine T. P. Besouw*, Johan G. Vande Walle, Mohamad I. Ilias ... Pediatric lupus nephritis presenting with terminal renal failure. / Besouw, Martine T. P.; Walle, Johan G. Vande; Ilias, ... Pediatric lupus nephritis presenting with terminal renal failure. 6 ed. 2016. 3 p. (Acta clinica belgica). doi: 10.1080/ ...
Flares of lupus nephritis (LN) cause acute kidney injury (AKI), even if serum creatinine (SCr) does not increase. Although ... Renal flare as a biomarker of incident and progressive chronic kidney disease in patients with lupus nephritis. *S Parikh1, ... Renal flare as a biomarker of incident and progressive chronic kidney disease in patients with lupus nephritis ... Renal flare as a biomarker of incident and progressive chronic kidney disease in patients with lupus nephritis. Arthritis Res ...
Lupus nephritis Lupus nephritis is inflammation of the kidney caused by systemic lupus erythematous (SLE). Also called lupus, ... Lupus nephritis happens when lupus involves the kidneys.. Up to 60% of lupus patients are likely to develop lupus nephritis. ... Lupus Nephritis Diagnosis and Treatment. The diagnosis of lupus nephritis begins with a medical history and evaluation of ... There are five different types of lupus nephritis. Treatment is based on the type of lupus nephritis, which is determined by ...
Lupus nephritis is a condition in which the the kidneys become inflamed as a result of systemic lupus erythematosus. Lupus ... commonly known as lupus, is a disease in which the the immune system produces proteins that attack the body and cause damage to ... nephritis can lead to impaired kidney function or, in extreme cases, kidney failure. ... Prevention of Lupus Nephritis. Because lupus nephritis is a common side effect of lupus, it cannot always be prevented. However ...
Bevra Hann professor of rheumatology at UCLA will introduce you to a person living with lupus nephritis. ... care and disease management of systemic lupus erythematosus (lupus). The grant is supported by the Centers for Disease Control ... Take Control.TM lupus awareness campaign, is featured in the January 2018 issue of The Rheumatologist. Be Fierce. Take Control. ... Multi-disciplinary lupus clinics provide patients with broader access to a variety specialists in one location. READ FULL ...
  • People with active lupus should not have a transplant because the condition can occur in the transplanted kidney. (medlineplus.gov)
  • Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. (suny.edu)
  • Elevated anti-double-stranded-DNA (anti-dsDNA) antibody titers and low complement (C3 and C4) levels often indicate active lupus nephritis and support the diagnosis. (msdmanuals.com)
  • This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN). (ucsf.edu)
  • Seventy-four eligible participants with active lupus nephritis (LN) will be randomized to receive VIB4920 1500 mg or placebo intravenously at Weeks 0, 2, 4, 8, 12, 16, 20, and 24. (ucsf.edu)
  • Renal involvement in the form of either active lupus nephritis (LN) at the time of conception, or a LN new onset or flare during pregnancy increases the risks of preterm delivery, pre-eclampsia, maternal mortality, fetal/neonatal demise, and intrauterine growth restriction. (elsevierpure.com)
  • 2. The panel recommended that all with active lupus nephritis, previously untreated undergo a renal biopsy but evidence for this was LEVEL C. (nephronpower.com)
  • The US Food and Drug Administration (FDA) has expanded the indication for belimumab (Benlysta) to adults with active lupus nephritis who are receiving standard therapy. (medscape.com)
  • Benlysta is the first medicine approved to treat systemic lupus and adults with active lupus nephritis, an important treatment advance for patients with this incurable autoimmune disease," Hal Barron, MD, GlaxoSmithKline's (GSK's) chief scientific officer and president of research and development, said in a company news release . (medscape.com)
  • The data from the BLISS-LN study show that Benlysta added to standard therapy not only increased response rates over two years, but it also prevented worsening of kidney disease in patients with active lupus nephritis compared to standard therapy alone," he added. (medscape.com)
  • Class IV disease (Diffuse proliferative nephritis) is both the most severe, and the most common subtype. (wikipedia.org)
  • The proliferative forms of lupus nephritis are associated with a higher risk of progression to end stage kidney disease. (wikipedia.org)
  • these are more common with focal (proliferative) and diffuse (proliferative) lupus nephritis. (medscape.com)
  • Proliferation signal inhibitors (PSI) have demonstrated efficacy in prevention and treatment in an animal model of lupus nephritis (LN) but there are no data regarding the use of PSI in human LN. We report here our experience of using PSI treatment in seven patients with severe proliferative lupus nephritis. (nih.gov)
  • This is a retrospective study on patients with proliferative lupus nephritis who had received PSI treatment. (nih.gov)
  • We identified 45 patients (38 female, seven male) who received a mean of 9 +/- 1 (range 2-23) pulses of intravenous cyclophosphamide for diffuse proliferative glomerulonephritis (n = 28), focal proliferative glomerulonephritis (n = 7), membranous nephropathy (n = 5), mesangial nephropathy with sclerosis (n = 1) or nephritis without biopsy (n = 4). (nih.gov)
  • We compared in patients with proliferative lupus nephritis the diagnostic usefulness of a dsDNA-loaded nucleosome ELISA (anti-dsDNA-NcX) with ELISAs in which dsDNA or nucleosomes alone were coated. (bath.ac.uk)
  • Second, autoantibody levels were measured in these 3 ELISAs in 100 patients with proliferative lupus nephritis (LN) before immunosuppressive treatment and in 128 non-SLE disease controls. (bath.ac.uk)
  • Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study. (suny.edu)
  • the secondary objective was to find which components of urinary sediment can discriminate proliferative from other classes of lupus nephritis . (bvsalud.org)
  • Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), an autoimmune disease. (wikipedia.org)
  • The diagnosis of lupus nephritis depends on blood tests, urinalysis, X-rays, ultrasound scans of the kidneys, and a kidney biopsy. (wikipedia.org)
  • The immune cell landscape in kidneys of patients with lupus nephritis. (broadinstitute.org)
  • With a previous grant from the LRA, Dr. Ooi studied which specific parts of the body were targeted by the misguided immune system in patients with lupus nephritis, a condition causing inflammation in the kidneys. (lupusresearch.org)
  • Lupus nephritis is a condition in which the the kidneys become inflamed as a result of systemic lupus erythematosus. (nephrologyspecialistsoftulsa.com)
  • Avoiding medications that can affect the kidneys also helps in lowering the risk of lupus nephritis. (nephrologyspecialistsoftulsa.com)
  • Lupus nephritis happens when lupus involves the kidneys. (saikidneycare.com)
  • Certain lupus medications can also affect the kidneys and cause swelling and other symptoms similar to those of lupus nephritis. (saikidneycare.com)
  • When lupus affects the kidneys, it is known as lupus nephritis. (cmneph.com)
  • Lupus most commonly affects your skin, joints, and Internal organs, like your kidneys and heart. (qualmedicaresearch.com)
  • December 16, 2020: The FDA approved on Wednesday DEC 16, 2020… Benlysta for lupus nephritis as the first drug ever FDA-approved to treat lupus nephritis (inflammation of the kidneys). (lupusencyclopedia.com)
  • Lupus causes the immune system to produce autoantibodies which attack the tissues and organs, including the kidneys, causing lupus nephritis. (iowakidney.com)
  • Want to read more about my journey with my kidneys and lupus? (blogspot.com)
  • New treatment options are needed for lupus nephritis, a potentially life-threatening inflammation of the kidneys that most commonly affects women," Sandra Horning, MD, chief medical officer and head of Global Product Development at Roche, said in a press release . (lupusnewstoday.com)
  • Roughly 40% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN), which causes inflammation in the kidneys and can lead to end-stage kidney disease. (medscape.com)
  • Neutralizing B-cell activating factor and down-regulating autoreactive B-cell function in kidneys" represents a "compelling therapeutic approach to lupus nephritis," the lead investigator of BLISS-LN, Richard Furie, MD, told the online annual Perspectives in Rheumatic Diseases meeting recently. (medscape.com)
  • In the ever-perilous autoimmune disease world of systemic lupus erythematosus (SLE or lupus), up to 60% of adult patients and 80% of children will develop lupus nephritis (LN), and up to half of those will move on to end-stage renal disease. (news-medical.net)
  • In two patients treated with PSI and low-dose steroid as maintenance immunosuppression, both maintained stable lupus serology, renal function and proteinuria over 18 months. (nih.gov)
  • Intermittent intravenous cyclophosphamide therapy of lupus nephritis is well tolerated and usually effective in maintaining renal function in patients unresponsive to steroids although, in our experience, 20% of patients developed ESRD and a total of 14 of 45 (30%) patients had unsatisfactory outcomes. (nih.gov)
  • In a 24-week open-label induction study of 370 patients with class III-V lupus, there were no differences in the primary end-point (a prespecified decrease in urine protein/creatinine ratio and stabilization or improvement in serum creatinine) or the secondary end-point (complete renal remission, systemic disease activity and damage, and safety). (ukidney.com)
  • Renal biopsy confirmed severe grade IV lupus nephritis. (rug.nl)
  • We describe an uncommon case of severe lupus nephritis, presenting with terminal renal failure. (rug.nl)
  • The renal domain of SLICC/ACR (Systemic Lupus International Collaborative Clinics/American College of Rheumatology) Damage Index (SDI) is associated with early mortality in SLE. (glomcon.org)
  • Antiphospholipid syndrome nephropathy increases a patient's risk of hypertension and renal insufficiency or failure compared with lupus nephritis alone. (msdmanuals.com)
  • However, there is good data that it can help decrease lupus inflammation in non-renal lupus. (lupusencyclopedia.com)
  • Renal balantidiasis associated with systemic lupus erythematosus has not been reported before. (ox.ac.uk)
  • Lupus nephritis is clinically evident in 50-60% of patients with systemic lupus erythematosus (SLE), and it is histologically evident in most SLE patients, even those without clinical manifestations of renal disease. (livingwithnephroticsyndrome.org)
  • Both CKD and lupus are risk factors for cardiovascular disease, although most studies of long-term renal outcomes in patients with lupus nephritis focus on end-stage kidney disease (ESKD) instead of CKD. (consultant360.com)
  • This study aimed to investigate baseline clinical features, treatment modalities and short- and long-term renal outcomes of paediatric patients with lupus nephritis (LN). Materials and methods This study enrolled 53 LN patients out of 102 childhood-onset SLE patients followed at Hacettepe University between 2000 and 2020. (ogu.edu.tr)
  • Evidence suggests a relative undertreatment of SLE patients with end-stage renal disease (ESRD), because the extent of lupus activity may be underestimated. (medscape.com)
  • Objective-- To estimate and identify factors associated with incidence of all-cause end-stage renal disease (ESRD) among newly diagnosed systemic lupus erythematosus (SLE) patients. (cdc.gov)
  • More than 5000 patients initiated treatment for end-stage renal disease (ESRD) attributed to systemic lupus erythematosus (SLE) in 2007-2011 (1). (cdc.gov)
  • Drug regimens prescribed for lupus nephritis include mycophenolate mofetil (MMF), intravenous cyclophosphamide with corticosteroids, and the immune suppressant azathioprine with corticosteroids. (wikipedia.org)
  • Several studies have suggested that mycophenolate mofetil (MMF) may be superior and less toxic than cyclophosphamide in the management of lupus nephritis. (ukidney.com)
  • All patients were treated with glucocorticoids, and 74% performed induction therapy with Protocol Euro-Lupus, followed by mycophenolate mofetil. (bmj.com)
  • To compare the efficacy and safety of mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVC) as induction treatment for lupus nephritis (LN), by race, ethnicity and geographical region. (suny.edu)
  • Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. (suny.edu)
  • Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. (suny.edu)
  • Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults. (bvsalud.org)
  • The World Health Organization has divided lupus nephritis into five stages based on the biopsy. (wikipedia.org)
  • Kidney biopsy should be considered in any patient with SLE who has clinical or laboratory evidence of active nephritis, especially upon the first episode of nephritis. (medscape.com)
  • This funding allows us to use artificial intelligence approaches to train a 'neural network' to learn how to read and classify lupus nephritis biopsy slides. (news-medical.net)
  • A kidney biopsy may also be performed to diagnose lupus nephritis. (nephrologyspecialistsoftulsa.com)
  • Treatment is based on the type of lupus nephritis, which is determined by the biopsy. (saikidneycare.com)
  • Lupus nephritis is diagnosed with blood and urine tests to measure kidney function, and a kidney biopsy to determine the severity of disease. (iowakidney.com)
  • 1. Definition of Lupus Nephritis included the usual persistent proteinuria, active sediment but noted that if a kidney biopsy showed immune complex mediated GN compatible with lupus nephritis would also qualify for the diagnosis. (nephronpower.com)
  • 3. Treatment of disease be based on the class of lupus identified on biopsy. (nephronpower.com)
  • To remedy this research gap, the investigators conducted a retrospective chart review to examine the development of CKD in a subset of patients with biopsy-proven lupus nephritis who had been followed up for at least 10 years at a single-center, lupus nephritis clinic. (consultant360.com)
  • The study followed up 72 patients for a median of 17 years after confirmation of lupus nephritis by kidney biopsy. (consultant360.com)
  • Methods Lupus nephritis patients scheduled for a kidney biopsy were included in our study. (bvsalud.org)
  • American College of Rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis. (medlineplus.gov)
  • In 2011, all lupus patients should receive hydroxychloroquine," Dr. David Wofsy flatly declared at a symposium sponsored by the American College of Rheumatology. (ukidney.com)
  • Classification of Systemic Lupus Erythematosus (SLE) by any of the following criteria: the 1997 update of the 1982 American College of Rheumatology (ACR) criteria (1, 2), the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria (3), or the 2019 European League Against Rheumatism (EULAR)/ACR criteria (4). (ucsf.edu)
  • General symptoms of lupus nephritis include Fever Edema High blood pressure Joint pain Muscle pain Malar rash Foamy urine The cause of lupus nephritis, a genetic predisposition, plays a significant role in lupus nephritis. (wikipedia.org)
  • What are the symptoms of lupus? (cdc.gov)
  • Symptoms of lupus vary and can appear off and on for years. (cdc.gov)
  • Black and Hispanic people with lupus nephritis are more likely to present with severe disease at initial presentation (with more proteinuria and more extensive histopathologic changes) and progress to end stage kidney disease. (wikipedia.org)
  • Lupus nephritis is a severe disease manifestation of SLE heterogeneity. (lupusresearch.org)
  • Lupus nephritis can be mild, moderate, or severe, and treatments plans are tailored to each patient individually. (cmneph.com)
  • If patients with more severe nephritis were preferentially treated with cyclophosphamide, a likely inclination among most physicians, the trial may be telling us that belimumab enhances responses only among less severely affected patients," observed Ward, who is with the National Institutes of Health, and Tektonidou, of the National and Kopodistrian University, in Athens, Greece. (medscape.com)
  • Background Childhood-onset systemic lupus erythematosus (SLE) is more severe than adult-onset disease, including more frequent kidney involvement. (ogu.edu.tr)
  • Black or African American and Hispanic/Latino women are more likely to get lupus at a younger age and have more severe symptoms. (cdc.gov)
  • Patients with C2 deficiency express many of the characteristic features of lupus, but severe nephritis, cerebritis, and aggressive arthritis are less common than in complement sufficient SLE patients. (lu.se)
  • Kidney inflammation caused by Systemic Lupus Erythematosus (SLE) is referred to as lupus nephritis or LN, and it is estimated that 40-50% of all SLE patients have LN requiring treatment. (pharmaphorum.com)
  • Lupus nephritis is inflammation of the kidney caused by systemic lupus erythematous (SLE). (saikidneycare.com)
  • Lupus nephritis is glomerulonephritis caused by systemic lupus erythematosus (SLE). (msdmanuals.com)
  • The medical records of patients receiving cyclophosphamide for lupus nephritis between 1987 and 1993 at the New York University/Hospital for Joint Diseases Lupus Study Group Institutions were retrospectively reviewed. (nih.gov)
  • Many nephrologists, myself included, are eager to find alternatives to cyclophosphamide in the management of lupus nephritis. (ukidney.com)
  • El Departamento de Fiscalía del Colegio de Farmacéuticos comunica sobre los requisitos para apertura y traslado de imuran for lupus nephritis . (onlinehome.us)
  • 4 Mar 2015 imuran for lupus nephritis . (onlinehome.us)
  • Farmacie Online Cialis imuran for lupus nephritis. (onlinehome.us)
  • Sientan una gran cantidad de farmacias de servicios de televisión por satélite con DISH Precio tienen claramente todo lo que vale su coche imuran for lupus nephritis . (onlinehome.us)
  • See who you know at Pharmacy Online, leverage your professional network, and get imuran for lupus nephritis . (cogdevelopment.com)
  • No Extra Fees imuran for lupus nephritis . (cogdevelopment.com)
  • Cialis works faster than other ED drugs imuran for lupus nephritis . (cogdevelopment.com)
  • Farmacia de Internet - Drogas baratas en linea imuran for lupus nephritis . (cogdevelopment.com)
  • In the phase III clinical trials, Benlysta IV (intravenous form) was added to the medicines we normally use to treat lupus nephritis (called standard of care, SOC). (lupusencyclopedia.com)
  • Your kidney doctor can treat lupus nephritis and help you maintain kidney function for as long as possible. (iowakidney.com)
  • Up to 60% of lupus patients are likely to develop lupus nephritis. (saikidneycare.com)
  • Once the diagnosis of lupus nephritis is established, a choice has to be made between the different induction treatment protocols. (rug.nl)
  • The diagnosis of lupus nephritis begins with a medical history and evaluation of symptoms. (saikidneycare.com)
  • Video - Dr. Bevra Hann professor of rheumatology at UCLA will introduce you to a person living with lupus nephritis. (thelupusinitiative.org)
  • In the four decades I have been caring for people with lupus, we have not been able to achieve remission in more than just one third of patients with lupus nephritis, and despite all of our efforts, 10% to 30% of patients with lupus kidney disease still progress to end-stage kidney disease," Furie, who is chief of the Division of Rheumatology at Northwell Health, notes in the GSK statement. (medscape.com)
  • If you have lupus nephritis, contact your provider if you notice decreased urine output . (medlineplus.gov)
  • Conclusions Evaluation of urine sediment reflects lupus nephritis histology . (bvsalud.org)
  • If you do have lupus, lupus is a chronic condition, but, you can control its symptoms. (mountsinai.org)
  • Lupus is a chronic (long-term) disease that can cause inflammation and pain in any part of your body. (qualmedicaresearch.com)
  • Living with a chronic illness like lupus nephritis can have a profound impact on a person's mental health. (infovitals.com)
  • Systemic Lupus Erythematosus (SLE) Systemic lupus erythematosus is a chronic, multisystem, inflammatory disorder of autoimmune etiology, occurring predominantly in young women. (msdmanuals.com)
  • Her book, "Despite Lupus: How to Live Well with a Chronic Illness", details the steps it took to reach that goal. (blogspot.com)
  • An analysis of 10-year follow-up data showed that immunosuppression may not be enough to prevent chronic kidney disease (CKD) in patients with lupus nephritis. (consultant360.com)
  • Lupus is a non-infectious and chronic autoimmune disease that affects different parts of the body. (cdc.gov)
  • Lupus is a chronic disease with no cure. (cdc.gov)
  • Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), more commonly known as lupus. (pipelinereview.com)
  • Systemic lupus erythematosus, commonly known as lupus, is a disease in which the the immune system produces proteins that attack the body and cause damage to the kidney, brain, joints and skin. (nephrologyspecialistsoftulsa.com)
  • Systemic lupus erythematosus, commonly known as lupus or SLE, is an autoimmune disease in which the a patient's immune system attacks his or her own body and causes damage to the kidney, brain, joints, skin, and other organs. (cmneph.com)
  • Autoimmune diseases, like lupus, are caused by the immune system mistakenly mounting pro-inflammatory responses against specific autoantigens. (lupusresearch.org)
  • KYV-101 is an autologous version of a novel, fully human clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties well suited for use in B cell-driven autoimmune diseases such as lupus nephritis and other B-cell driven autoimmune diseases. (pipelinereview.com)
  • However, its mechanism of action also suggests Gazyva may be useful to prevent excessive inflammation associated with several autoimmune diseases , including lupus . (lupusnewstoday.com)
  • People with a family history of lupus or other autoimmune diseases. (cdc.gov)
  • A rheumatologist is a doctor who specializes in the diseases of joints, muscles, and systematic autoimmune diseases such as lupus. (cdc.gov)
  • Cite this: FDA Expands Belimumab Indication to Adults With Lupus Nephritis - Medscape - Dec 18, 2020. (medscape.com)
  • The pathophysiology of lupus nephritis has autoimmunity contributing significantly. (wikipedia.org)
  • Individuals with lupus nephritis have a high risk for B-cell lymphoma (which begins in the immune system cells). (wikipedia.org)
  • Pathway analysis indicated that biological processes involving type 1 interferon responses and the development of the immune system were associated with nephritis in patients with SLE. (escholarship.org)
  • Systemic Lupus Erythematosus (SLE) is an autoimmune disease that varies in severity in which the patient's immune system mistakenly attacks healthy tissues in the body. (chop.edu)
  • In a person with lupus, the immune system attacks healthy tissues and organs, instead of fighting off infection. (cdc.gov)
  • Findings from this study will provide a foundation for clinical studies testing a potentially first-in-class therapy for lupus nephritis that uses specialized regulatory T cells to treat and even possibly cure this disease. (lupusresearch.org)
  • Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S. (pipelinereview.com)
  • We are committed to developing Gazyva as a potential new therapy for lupus nephritis and plan to begin enrolling patients in a Phase 3 trial next year. (lupusnewstoday.com)
  • On kidney failure, people with lupus nephritis may need dialysis. (saikidneycare.com)
  • The goal of using AI to classify lupus nephritis in an automated fashion with high accuracy will translate to better treatment for lupus nephritis, according to researchers. (news-medical.net)
  • Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is ineffective and often toxic. (broadinstitute.org)
  • Proliferation signal inhibitors warrants further investigation as an alternative immunosuppressive treatment in lupus nephritis. (nih.gov)
  • Dr. Ooi has pioneered the approach of developing specialized regulatory T cells that may be used as a future treatment for lupus nephritis patients. (lupusresearch.org)
  • Current approaches, including newly approved biologicals, are ineffective at improving treatment outcomes for SLE patients with lupus nephritis. (lupusresearch.org)
  • Treatment focuses on reducing inflammation and treating the underlying cause of lupus. (nephrologyspecialistsoftulsa.com)
  • Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. (suny.edu)
  • Lupus Nephritis Treatment - What is Next? (glomcon.org)
  • The kidney doctors at Iowa Kidney Physicians provide comprehensive kidney treatments, including diagnosis and treatment of lupus nephritis. (iowakidney.com)
  • To find out more about diagnosis and treatment of lupus nephritis, call the kidney doctors at Iowa Kidney Physicians in Des Moines, IA. (iowakidney.com)
  • You've done your part to help further LN research and help scientists and researchers develop better diagnostic tools and treatment options for lupus nephritis patients. (blogspot.com)
  • Some of the other things the task force discusses is changing regimen when initial treatment fails, pregnancy related to SLE treatment options and monitoring of lupus nephritis. (nephronpower.com)
  • The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Gazyva ( obinutuzumab ) for the treatment of adult patients with lupus nephritis , a life-threatening kidney inflammation. (lupusnewstoday.com)
  • This means that people with lupus can manage their condition with treatment, but it will not go away. (cdc.gov)
  • Treatment can help improve symptoms, prevent flares, and prevent other health problems caused by lupus. (cdc.gov)
  • [ 99 ] In 2012, the ACR published " Guidelines for the Screening, Diagnosis, Treatment and Monitoring of Lupus Nephritis in Adults ," as well as an evidence report for lupus nephritis . (medscape.com)
  • Furthermore, using our custom lentiviral vectors and Treg transduction processes, we have genetically engineered therapeutic targeted Tregs specific for the dominant autoimmune target driving lupus nephritis (PCT patent filed). (lupusresearch.org)
  • In this 2021 LIA application, we are seeking to manufacture our targeted Tregs using GMP-ready processes and test the therapeutic efficacy on lupus nephritis patient samples. (lupusresearch.org)
  • abstract = "Lupus nephritis (LN) is among the main determinants of poor prognosis in systemic lupus erythematosus (SLE). (northwestern.edu)
  • ABSTRACT This study assessed the utility of some novel inflammatory markers compared with traditional laboratory markers in patients with systemic lupus erythematosus (SLE). (who.int)
  • this is more typical of mesangial or membranous lupus nephritis. (medscape.com)
  • New study findings show women with lupus nephritis (LN, lupus-related kidney disease) - especially those with active LN - are at significantly increased risk of pregnancy complications compared to women with lupus without LN. Adverse pregnancy outcomes included fetal loss (miscarriage or stillbirth), preterm birth (childbirth that occurs before 37 weeks of pregnancy) and preeclampsia (a pregnancy complication characterized by high blood pressure and organ system damage). (lupus.org)
  • Researchers assessed data from 393 women with lupus in the United States and Canada, 37% of whom had a history of LN. Those with a history of LN had almost twice the odds of poor pregnancy outcomes compared to women without LN. (lupus.org)
  • The Lupus Foundation of America works to improve the quality of life for all people affected by lupus through programs of research, education, support and advocacy. (lupus.org)
  • Take Control.TM was jointly created by the ACR and the Lupus Foundation of America (LFA) and launched in June 2018. (thelupusinitiative.org)
  • Sara Gorman was diagnosed with systemic lupus at the age of 26. (blogspot.com)
  • There are five different types of lupus nephritis. (saikidneycare.com)
  • There are different types of lupus that affect different organs and systems, including skin, muscle, kidney, and heart. (cdc.gov)
  • There is now solid evidence that hydroxychloroquine (Plaquenil) prevents lupus flares, treats the skin manifestations of the disease, protects against thromboembolic events, prevents cardiac neonatal lupus, and prolongs life. (ukidney.com)
  • Flares of lupus nephritis (LN) cause acute kidney injury (AKI), even if serum creatinine (SCr) does not increase. (biomedcentral.com)
  • Women can take steps to control symptoms, prevent lupus flares, and cope with the challenges of lupus. (cdc.gov)
  • The LUMINA (Lupus in Minorities: Nature versus Nurture) study and other trials have offered evidence of a decrease in flares and prolonged life in patients given hydroxychloroquine, making it the cornerstone of SLE management. (medscape.com)
  • The principal goal of therapy in lupus nephritis is to normalize kidney function or, at least, to prevent the progressive loss of kidney function. (medscape.com)
  • Lupus nephritis can lead to impaired kidney function or, in extreme cases, kidney failure. (nephrologyspecialistsoftulsa.com)
  • Lupus Nephritis impacts kidney function and is associated with significant morbidity and mortality, even with current treadtments. (qualmedicaresearch.com)
  • Lupus nephritis can lead to poor kidney function and kidney failure. (iowakidney.com)
  • Lupus Nephritis (LN) is kidney inflammation, which is a complication of SLE that causes decreased kidney function. (chop.edu)
  • Kidney function in patients with lupus nephritis followed up for a very long time. (consultant360.com)
  • a classification tree was calculated to select a set of values that best-predicted lupus nephritis classes. (bvsalud.org)
  • These findings have not been identified in genetic studies of lupus nephritis, suggesting that epigenome-wide association studies can help identify the genomic differences that underlie the clinical heterogeneity of SLE. (escholarship.org)
  • 8. Euro Lupus ( 500mg of IV CYC every 2 weeks) for total of 6 doses be used for Caucasians and patients of European origin and the NIH protocol( 500-1000mg/m2 IV once a month for 6 doses) be used for the rest. (nephronpower.com)
  • The characteristics of nephritogenic autoantibodies (lupus nephritis) are antigen specificity directed at nucleosome, high affinity autoantibodies form intravascular immune complexes, and autoantibodies of certain isotypes activate complement. (wikipedia.org)
  • Autoantibodies against nucleosomes are considered a hallmark of systemic lupus erythematosus (SLE). (bath.ac.uk)
  • Systemic lupus erythematosus (SLE) is a clinically heterogeneous multi-system disease, that is characterised by the presence of autoantibodies directed against nuclear antigens. (bmj.com)
  • How well you do depends on the specific form of lupus nephritis. (medlineplus.gov)
  • Researchers estimate that 200,000 1 Americans have systemic lupus erythematosus (SLE), the most common form of lupus. (cdc.gov)
  • Those most affected by this form of lupus are African American, Hispanic/Latino, and Asian American women. (cdc.gov)
  • the latter are thought to play a role in lupus. (medscape.com)